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Project 1: Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride 
(TG) levels in adipocytes through multiple pathways, with AMP-activated protein kinase 
(AMPK) generally facilitating, and peroxisome proliferator-activated receptor γ (PPARγ) 
generally opposing these reductions. Sirtuin 1 (SIRT1), a histone/protein deacetylase that 
affects energy homeostasis, often functions coordinately with AMPK, and is capable of 
binding to PPARγ, thereby inhibiting its activity. This study investigated the role of 
SIRT1 in the response of 3T3-L1 adipocytes to t10c12 CLA by testing the following 
hypotheses: 1) SIRT1 is functionally required for robust TG reduction; and 2) SIRT1, 
AMPK, and PPARγ cross regulate each other. Inhibition of SIRT1 amounts or activity 
attenuated the amount of TG loss, while SIRT1 activator SRT1720 increased the TG loss. 
SRT1720 increased AMPK activity while sirtuin-specific inhibitors decreased AMPK 
activity. Reciprocally, an AMPK inhibitor reduced SIRT1 activity. Treatment with 
t10c12 CLA increased PPARγ phosphorylation in an AMPK-dependent manner and 
increased the amount of PPARγ bound to SIRT1. Reciprocally, a PPARγ agonist 
attenuated AMPK and SIRT1 activity levels. These results indicated SIRT1 increased TG 
loss and that cross regulation between SIRT1, AMPK, and PPARγ occurred in 3T3-L1 
adipocytes treated with t10c12 CLA. 
 
  
Project 2: In the current study profiling of 261 metabolites was conducted to gain new 
insights into the biological pathways responding to t10c12 CLA in 3T3-L1 adipocytes.  
Sphingonine, sphingosine, and ceramide levels were observed to be highly elevated in 
t10c12 CLA treated adipocytes. Exogenous chemicals that increase endogenous ceramide 
levels decreased lipid levels in adipocytes, and activated AMPK as well as nuclear factor 
kappa-B (NF-κB), both of which are normally activated in CLA treated adipocytes. 
Concurrent inhibition of de novo ceramide biosynthesis and entry from existing 
sphingoglipid pools attenuated the lipid lowering and apoptotic effects normally 
associated with responses to t10c12 CLA. Our results indicate ceramides are an important 
component of the lipid lowering response in t10c12 CLA treated adipocytes. 
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Trans-10, Cis-12 Conjugated Linoleic Acid and Delipidation 
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Introduction 
Obesity has become a global problem. In 2010, 6.7% children (43 million) were 
estimated to be overweight, and this incidence keeps increasing [1]. World Health 
Organization (WHO) predicted that there will be about 2.3 billion overweight adults by 
2015 worldwide and over 1/3 of them will be obese [2]. In the United States, obesity 
incidence increased 24% from 2000 to 2005. Keeping this trend, there will be about 50% 
obese adults and 30% obese children respectively in the U.S. by 2030 [3,4]. Obesity has 
been associated with numerous diseases, including type 2 diabetes mellitus, breathing 
difficulties during sleep, hypertension, heart disease, stroke and even certain types of 
cancer [5,6]. For women, prenatal obesity is associated with gestational hypertension, 
preeclampsia, large-for-gestational-age (LGA) baby and higher incidence of congenital 
defects [7]. The most popular treatments for obesity are exercise-plus-diet which needs a 
long term lifestyle modification or a bariatric surgery, which has an unexpected prognosis 
[8]. Convenient and effective method for obesity therapeutic treatment is urgently 
demanded.   
 
Trans10, cis12 conjugated linoleic acid (t10c12 CLA) has been established to causes a 
strong delipidation in vitro in mouse and human adipocytes, and in mice [9-12]. 
Applications in human trials have had modest results. T10c12 CLA belongs to the C18 
linoleic acid  fatty acid family which contain at least 28 isoforms. T10c12 CLA is a 
polyunsaturated fatty acid which has a lipid number of 18 and 2 double bonds in the 10th 
and 12th carbons. Conjugated double bonds are separated by a single bond to form trans-
10, cis-12 octadecadienoic acid. CLA is found primarily in the meat and dairy products of 
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ruminants. Anaerobic bacteria convert linoleic acid into different isoforms of CLA via 
biohydrogenation [13]. Several isoforms of CLA have been identified but the cis-9, trans-
11 isoform (rumenic acid) is the predominant form in ruminant products (about 90%). 
Though t10c12 CLA isoform comprises only 10%, it is specifically responsible for the 
CLA induced delipidation effect [14-17].  
 
Biological effects of CLA 
CLA has been shown to have several beneficial effects such as anti-carcinogenic [18,19], 
anti-atherogenic [20-22], anti-diabetogenic [23] and anti-obesity [24-26] properties. CLA 
was initially discovered and identified as an anticarcinogen in 1987 [27]. Park’s group 
firstly reported the delipidation effect of CLA in 1997 [28]. In their study, both male and 
female mice lost nearly 60% body fat after 5 weeks of dietary supplementation with 0.5% 
t9c11/t10c12 CLA mixture (1:1 wt/wt). Subsequent studies showed that supplementation 
with a CLA mixture (t10c12 and c9t11 isoforms) or the t10c12 isoform alone decreased 
body fat mass in murine [28-30], chicken [31], rabbit [32], pigs [33] and some human 
studies [24-26]. Later studies proven this delipidation effect is attributed to the t10c12 
isoform [34,35]. Our previous data demonstrated that mice lost more than 75% of white 
adipose tissue mass in the retroperitoneal and epididymal fat pad after 2 weeks 
consumption of 0.5% t10c12 CLA [9]. Yet, CLA induced body fat losses may be 
reversible, as removal of CLA from diet result in recover of triglyceride accumulation 
[36].  
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In vitro, t10c12 CLA induced delipidation occurs in mouse 3T3-L1 and human primary 
adipocytes. Concentrations of 50-200µM of t10c12 CLA caused a dose dependent 
triglyceride loss in 3T3-L1 adipocytes [37]. In our previous study, 50µM and 100µM 
t10c12 CLA caused the robust loss of triglyceride content by 25% and 50% respectively 
in 3T3-L1 adipocyte compare to control group [38]. The McIntosh group recently 
confirmed t10c12 CLA induced delipidation in human primary adipocyte. 30 µM t10c12 
CLA decreased synthesis of triglyceride, free fatty acid, diacyglycerol, cholesterol esters, 
cardiolipin and phospholipids within 3-24 h [39].   
 
CLA induced delipidation effect in human studies are controversial. Some studies 
reported that supplementation of CLA result in increased body lean mass and decreased 
body fat mass [26,40,41]. However, most human studies showed that there is no 
significant delipidation effect of CLA on body composition. For example, 
supplementation of t9c11/t10c12 CLA mixture (1:1 wt/wt) for 14 weeks had no effect on 
body composition in healthy adults [42]. In another study, supplementation of 3 gram 
CLA mixture daily could not prevent body weight regain in moderately obese subjects 
who had lost 10 kilogram weight previously via limiting calorie intake [43]. Finally, the 
Arnaiz group did show positive delipidation effect of CLA mixture, but only in 
overweight subjects, not in obese subjects [44]. Dosage differences between animal and 
human studies may contribute to these contradictory findings. A typical dosage of CLA 
in human study is approximately 0.05g/kg body weight. As comparison, a typical dosage 
used in mouse studies is about 1.05g/kg body weight, which is 20 times the human dose. 
Additionally, human studies have gender, weight, age and healthy status differences, 
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which increase the complexity of interpreting any outcomes. Our goal is to combine 
t10c12 CLA with other nutritional supplements to attain synergistic interactions to induce 
a respectable fat loss at a lower CLA dose. This has great therapeutic potential for 
treating human obesity.   
 
Potential mechanism 
T10c12 CLA alters energy homeostasis 
Biological homeostasis between energy intake and energy expenditure is critical for 
maintaining body weight. A potential mechanism by which t10c12 CLA induces 
delipidation is by decreasing energy intake and/or increasing energy expenditure. 
Supplementation of CLA mixture or t10c12 CLA has been shown to modestly reduce 
feed intake in mice [28,35,45]. The delay in the effect of CLA on a feed intake reduction 
indicates CLA might exert its effort indirectly [46,47]. A suggested mechanism for this 
reduction in feed intake is CLA may regulate hypothalamic appetite-regulating genes. 
The Li group demonstrated that supplementation of CLA for 27 days decreased gene 
expression ratio of proopiomelanocortin (POMC) to neuropeptide Y (NPY) in 
hypothalamus [45]. In another study in rat, hypothalamic injection of a CLA mixture 
reduced the expression of neuropeptide Y (NPY) and agouti-related protein (AgRP) 
while elevated circulating leptin level [48]. However, most studies showed that t10c12 
CLA has little effect on feed intake [49-52]. In our previous study, Mice fed 0.5% t10c12 
CLA for 14 days lost 85% of their white adipose tissue and didn’t change their feed 
intake  [9]. Additionally, CLA-mediated reduction in feed intake tends to diminish over 
time while the reduction in body fat is maintained [47,53]. These results indicate that 
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CLA-mediated feed intake reduction via regulating neuronpeptide may partially 
contribute to its delipidation effects.   
 
In the case of energy expenditure, t10c12 CLA was reported to increase energy 
expenditure via increasing basal metabolic rate, thermogenesis or lipid oxidation. In a 
human study, consumption of 1.8 g or 3.6 g CLA/day for 14weeks increased resting 
metabolic rate in both sexes compare to a placebo group  [54]. Supplementation of CLA 
mixture or the  t10c12 isoform has been proven to induce uncoupling proteins 2 (UCP2) 
transcription in white adipose tissue [9,55]. UPC2 is the most highly expressed 
uncoupling protein and can be found in a variety of tissues including white adipose tissue. 
Uncoupling proteins (UCPs) are mitochondrial inner membrane proteins that divert ATP 
synthesis to heat production. In Balb-C mice, supplementation of CLA for 39 days 
increased the percentage of energy expenditure as heat [50]. Our previous study also 
demonstrated that 0.5% t10c12CLA supplementation for 2 weeks increased UCP1 and 
UCP2 transcriptional levels in mice [9]. T10c12 CLA was also reported to increase 
carnitine palmitoyltransferase 1 (CPT1) levels which is the rate-limiting enzyme for fatty 
acid beta-oxidation in the mitochondria. Our previous study demonstrated that 0.5%  
t10c12 CLA supplementation for 2 weeks increased CPT1 mRNA level in fat tissue [9]. 
Consistent with this findings,  t10c12 CLA  was reported to increase beta-oxidation in 
differentiating 3T3-L1 preadipocyte [56].  
 
Activation of UCPs increases the ratio of AMP to ATP, which activates 5’-AMP-
activated protein kinase (AMPK) [57]. AMPK, activated by phosphorylation, is a central 
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regulator of cellular energy levels. Activated AMPK regulates a number of substrates’ 
activity by phosphorylation, including activation of hormone sensitive lipase (HSL) 
which leads to activation of lipolysis [58], and deactivates acetyl CoA carboxylase (ACC) 
which result in lipogenesis suppression [59]. Activation of AMPK was observed as early 
as 0.5 h in response to t10c12 CLA treatment in 3T3-L1 adipocyte [38]. AMPK inhibitor 
compound C attenuated the ability of t10c12 CLA to induce triglyceride loss while its 
agonist metformin strengthened t10c12 CLA’s ability. These data suggest that the 
activation of AMPK plays an important role in t10c12 CLA induced delipidation.  
 
t10c12 CLA inhibits lipogenesis 
Lipogenesis is the process by which acetyl-CoA is converted to fatty acids, which are 
subsequently esterified with glycerol to form triglycerides. Our previous study 
demonstrated that t10c12 CLA decreased Sterol regulatory element-binding proteins 
(SREBP) 1c expression in 3T3-L1 adipocyte [38]. SREBPs are transcription factors that 
regulate sterol biosynthesis.  The activation of SREBPs is controlled by sterol levels 
through negative feedback regulation. When cell sterol levels are low, SREBPs are 
activated by cleavage.  Activated SREBPs translocate to the nucleus where they bind to 
specific sterol regulatory element DNA sequence, regulating the synthesis of enzymes 
involved in sterol biosynthesis. Among all isoforms, SREBP-1c is responsible for 
regulating the genes required for lipogenesis. By down regulating SREBP-1c, t10c12 
CLA decreased numerous proteins involved in lipogenesis such as ACC, fatty acid 
synthase (FAS), stearoyl-CoA desaturase (SCD), lipoprotein lipase (LPL), glycerol 
phosphate acyltransferase and acylglycerol phosphate acyltransferase [9,60]. Additionally, 
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t10c12 CLA may also inhibits lipogenesis via suppressing peroxisome proliferator-
activated receptor γ (PPARγ) activity. PPARγ is a type II nuclear receptor that regulates 
transcription of various downstream lipogenic genes, including glycerol-3-phosphate 
dehydrogenase, LPL, lipin and perilipin [61]. Our microarray data also showed that in 
mice or 3T3-L1 adipocytes, t10c12 CLA decreased the mRNA levels of some other 
lipogenic genes, including ATP citrate lyase, ACC-α and -β, caveolin I and lipin 1[9]. 
T10c12 CLA inhibits adipogenesis  
Adipogenesis is the process of differentiation of preadipocytes to adipocytes. This 
process involves the activation of key transcription factors including PPARγ, PPARγ co-
activators, fatty acid binding proteins (aP2) and CAAT/enhancer binging protein (C/EBP). 
CLA has been proven to suppresses preadipocyte differentiation by attenuating PPARγ, 
C/EBPα, SREBP 1c, liver X receptor α (LXRα) and aP2 expression [60,62-64]. Besides 
down regulation of PPARγ expression, t10c12 CLA treatment also decreases PPARγ 
activity and its target genes’ expression [65,66]. The McIntosh group demonstrated that 
CLA may inhibit PPARγ activity via mitogen-activated protein kinase (MAPK) pathway 
which leads to PPARγ phosphorylation [12]. Because the expression of PPARγ is directly 
or indirectly induced by itself, deactivated PPARγ suppresses its own expression and its 
target genes. In preadipocytes, our previous study showed that t10c12 CLA increased the 
expression of preadipocyte factor 1(Pref 1), which inhibits adipogenesis via suppressing 
the expression of PPARγ and C/EBPα [9].  
 
t10c12 CLA promotes lipolysis 
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Several studies have reported that t10c12 CLA increase lipolysis in 3T3-L1 and human 
adipocytes [28,67]. Lipolysis is the process by which stored triglyceride is mobilized and 
hydrolyzed into free fatty acid (FFA) and glycerol through the action of HSL. CLA may 
induce lipolysis via liberating FFA for uptake in metabolically active tissues like liver 
and muscle. Perilipin coats lipid droplets act as a protective barrier to prevent HSL 
accessing to neutral lipid substrates[68]. Perilipin is activated by protein kinase A (PKA, 
also known as cAMP-dependent protein kinase) and then exposing the stored lipids to 
HSL. Among all isoforms, perilipin A is the most abundant protein associated with 
adipocyte lipids [69]. Adipocyte differentiation-related protein (ADRP) is another lipid 
droplet-associated protein that facilitates lipid deposition or hydrolysis. Compare to 
perilin, ADRP is found on the surface of small lipid droplets rather than larger lipid 
droplets. McIntosh’s group demonstrated that t10c12 CLA increased lipolysis in human 
stromal vascular cells. In this research, t10c12 CLA alteration of adipocyte morphology 
was explained by elevated lipolysis and replacement of perilin by ADRP [67].  
 
CLA may also promotes lipolysis via increasing HSL expression. Our previous study 
showed that supplementation of t10c12 CLA for 3 days in C57BL/6J mice increased HSL 
mRNA level [9]. Released glycerol and FFA from lipolysis can be reused to synthesize 
triglyceride which is an ATP dependent process. Lipolysis followed by this futile cycle 
may partially explain CLA induced energy expenditure increases. Consist with this 
mechanism, OLETF rat supplemented with CLA for 4 weeks lost 5% body weight and 
had lower serum FFA levels  compare to control group [70]. In vitro, a study also 
confirmed that CLA treatment reduced glycerol release from rat adipocytes [71].  
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t10c12 CLA causes insulin resistance  
CLA mixture or t10c12 isoform has been reported to induce insulin resistance in mice 
and humans [72-74]. T10c12 CLA supplementation also results in hyperinsulinia, which 
is associated with insulin resistance [75-77].  Insulin enhances glucose uptake in muscle 
and adipose tissue and inhibits release of fatty acids in adipose tissue. Insulin resistant 
cells fail to response to insulin, cannot take in glucose, amino acid and fatty acid, leading 
to hyperglycemia. Additionally, insulin activates LPL and inhibits HSL in adipocyte 
[78,79], which result in decreased LPL-mediated lipogenesis and ineffective inhibition of 
HSL-mediated lipolysis in adipose tissue. CLA may induce insulin resistance via 
suppressing translocation or expression of glucose transporters (GLUT). Glucose 
transporters, which facilitate translocation of glucose over a plasma membrane, play an 
important role in insulin action. McIntosh’s group demonstrated that t10c12 CLA 
inhibited glucose uptake in primary human adipocytes by decreasing glucose transporter 
4 (GLUT 4) gene expression [60]. In our previous study, supplementation of t10c12 CLA 
decreased glucose/fructose transporter GLUT 5 mRNA level in 3T3-L1 adipocyte and 
mice white adipose tissue [9].  
 
CLA may also induce insulin resistance through regulating adiponectin. Besides 
regulating glucose level and fatty acid oxidation, adiponectin directly sensitizes the body 
to insulin and plays a protective role against insulin resistance [80,81]. Disruption of 
adiponectin caused insulin resistance in mice [82]. Supplementation of CLA decreased 
adiponectin mRNA level in mice, rat, 3T3-L1 adipocyte and human adipocyte [71,83-85]. 
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Because adiponectin is regulated by PPARγ, its reduction may partly result from CLA’s 
suppression of PPARγ.  
 
t10c12 CLA causes inflammation 
t10c12 CLA has been reported causes inflammation in 3T3-L1 adipocytes [9]. 
Proinflammatory cytokines, which can be produced by white adipose tissue, promote 
inflammation in adipocytes by suppressing lipid synthesis and increasing lipolysis. 
Nuclear factor kappa-B (NF-κB) regulates many cytokines genes like tumor necrosis 
factor alpha (TNFα) and interleukin (IL). T10c12 CLA has been demonstrated to increase 
the expression or secretion of TNFα, IL-1β, IL-6, IL-8, IL-10, IL-15, IL-17 [9,73,83,85], 
which suppress PPARγ activity and insulin sensitivity. McIntosh’s group showed that 
t10c12 may up-regulate these cytokines via activation of ERK1/2 and NF-κB. These 
secreted cytokines activate their cognate cell surface receptors which in turn activate NF-
κB and ERK1/2.  Consequently, activated NF-κB p65 results in suppression of PPARγ, 
LPL, FAS, GLUT4, aP2, sterol-CoA desaturase (SCD) and perilipin [73]. Interestingly, 
our microarray data suggests that t10c12 CLA induced inflammatory response may be 
transient. Most of these gene’s expression reduced to normal or even lower level after the 
first week of  t10c12 CLA treatment [9].   
 
The inflammation response in t10c12 CLA treated cell may be initiated by an integrated 
stress response (ISR). ISR is characterized by the phosphorylation of the α subunit of 
eukaryotic translation initiation factor 2 (eIF2α) under endoplasmic reticulum stress, 
amino acid starvation or oxidants.  Phosphorylation of eIF2α also increases the release of 
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proinflammatory cytokines by activating NF-κB and decreasing NF-κB inhibitor IkappaB 
level [86,87]. In our study, phosphorylation of eIF2α by t10c12 CLA treatment increased 
occurred earlier than the increase in the mRNA levels of genes involved in the ISR, 
including activating transcription factor 3 (ATF3), C/EBP homologous protein (CHOP) 
and pseudokinase tribbles 3 (TRB3) which are involved in cell apoptosis [88]. 
Microarray data analysis indicated that IRS is the earliest transcriptional response that 
occurs in t10c12 CLA treated 3T3-L1 adipocytes and mice, prior to the induction of 
proinflammatory cytokines such as IL-6 and IL-8 [9]. These data suggest that ISR plays 
an early important role in induction of the later inflammation and apoptosis.  
 
 t10c12 CLA causes moderate apoptosis 
Apoptosis was thought to be the major mechanism of t10c12 CLA induced triglyceride 
loss [46,56,89]. Apoptosis is a process of programmed cell death (PCD) in organisms. 
Our recent studies in mouse model showed that supplementation of t10c12 CLA reduced 
adipocyte numbers by 15% and cell volumes by 90% in fat tissues. Our microarray 
analysis also demonstrated that t10c12 CLA increased numerous gene expression 
involved in apoptotic signaling and DNA repair, including TNF ligands, TNF responsive 
genes, MdM-2, APAF1, BAX, PMAIP1, MCL1, PCNA,GADD45B, CDKNA1 (pRB), 
caspases 1 and 4 [9]. 
  
Our recent metabolite studies indicate CLA may causes apoptosis via regulating 
sphingolipid biosynthesis. Ceramide, sphingosine and shpingosine-1-phosphytate (S1P) 
are interconvertible sphingolipid metabolites. Ceramide and S1P exert opposite effort in 
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cell survival [90,91]. Conversion of sphingosine to S1P enhances cell growth and 
survival while dephosphorylation of S1P to sphingosine, which is acylated to form 
various ceramides, has been shown to be associated with growth arrest and apoptosis [92]. 
Ceramide plays an important role in initiating apoptotic events at the plasma membrane. 
Ceramide can be generated from either de novo synthesis or sphingomyelin hydrolysis 
[93-95].  In some apoptosis models, ligands (FAS, TRAIL) binding to their specific death 
receptor or stress stimuli activate sphingomyelinase [96-98] which translocate from 
cytosol to outer plasma membrane [99]. Hydrolysis of sphingomyelin by 
sphingomyelinase turns lipid rafts, which is enriched in sphingolipids[100], to ceramide 
enriched platforms [98,101,102].  These platforms are considered to be instrumental in 
reorganization of signaling molecules and clustering of receptor molecules at the cell 
membrane [103,104]. In Fas induced apoptosis, clustering of receptor recruit Fas-
associated death domain (FADD) and caspase-8 which forming the death-inducing 
signalling complex (DISC) [105].  
 
In mitochondria, ceramides synergize with Bax to increase outer membrane permeability 
[106]. On one hand, ceramides faciliate Bax and/or Bak oligomerization, which form 
mitochondrial apoptosis channel in the outer membrane [107,108]. On the other hand, 
ceramides may also induce channels in the mitochondrial membrane [109-111]. 
Formation of these channels lead to leakage of apoptogenic factors such as cytochrome c, 
apoptosis inducing factor, and DIABLO into the cytosol which facilitating the formation 
of apoptosome complex [112].  In lysosomes, ceramide generation activates aspartic 
protease Cathepsin D which then cleaves and activate pro-apoptotic protein BH3 
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interacting domain death agonist (BID) [113]. Truncated BID leads to activation of 
cysteine-aspartic proteases (caspase), resulting in apoptosis[114]. 
 
The mechanism of how t10c12 CLA elevates ceramide levels remains unknown. Since no 
specific receptor for t10c12 CLA has been reported, lipid rafts may play an intermediate 
role in the process. Increasing evidence indicates that long chain polyunsaturated fatty 
acid (PUFA), like DHA, could alter lipid rafts behavior and protein function [115]. 
Docosahexaenoic acid (DHA) has been proven to alter basic properties of cell 
membranes, including elastic compressibility, ion permeability, fusion, the size and 
distribution of lipid rafts [115,116].  Eicosapentaenoic acid (EPA) and DHA have been 
demonstrated to decrease lipid raft sphingomyelin and increase lipid raft ceramide levels 
in human breast cancer cells[117]. These results provide a potential role of CLA in 
incorporating into sphingolipid rich raft domain and modulating ceramide level.  
 
It is also unclear in t10c12 CLA induced triglyceride loss, what level of apoptosis is 
caused by ceramides. Our previous study based on microarray analysis indicated that 
apoptosis may be not the main effect on t10c12 CLA induced delipidation [9]. In our 
research, only moderate levels of adipocyte underwent apoptosis. These results indicated 
that sphingosine-1-phosphate may also play a role in attenuating cell death.   
 
Conclusion and implication 
T10c12 CLA causes robust delipidation in cultured adipocytes, animal models and some 
human studies. The potential mechanism responsible for its delipidation properties is 
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associated with increased energy expenditure, lipolysis, fatty acid oxidation, 
inflammation, apoptosis and decreased energy intake, adipogenesis, lipogenesis.  
 
Sirtuin 1, a member of the sirtuin family, is a NAD-dependent protein deacetylase. 
Sirtuin 1 can repress PPARγ activity by interacting with its cofactors, including nuclear 
receptor co-repressor (NCoR) and silencing mediator of retinoid and thyroid hormone 
receptors (SMRT) [118]. Sirtuin 1 is also reported to cooperate with AMPK to regulate 
energy-metabolism gene expression in mouse skeletal muscle [119]. AMPK and SIRT1 
are believed to cross regulate each other and share many common target molecules [120]. 
Besides, Sirtuin 1 is reported regulates the transcriptional activity of NF-κB deacetylating 
subunit [121]. Given that PPARγ, NF-κB and AMPK are essential in t10c12 induced 
delipidation, we highly suspect that sirtuin 1 is involved in this process.  
 
Recently, we conducted a metabolic profiling analysis of 3T3-L1 adipocytes treated with 
either 100 µM LA or t10c12 CLA for 0.5 h or 12 h for the purpose of identifying early 
changes in metabolites in these cells. The most striking change was a 9.8 fold increase in 
sphinganine and a 3.6 fold increase in sphingosine. This indicates the sphingolipid 
pathway is highly elevated after t10c12 CLA treatment. Due to the opposite effect of 
sphingolipid metabolites on cell survival and apoptosis [90,91], it is important to find out 
the role of the ceramide pathway in t10c12 CLA induced delipidation.  
 
Based on these data, my thesis attempt to answer the following questions.  
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1. Whether Sirtuin 1 is required for t10c12 CLA induced delipidation and how it exerts 
its effort to this process.  
2. What is the role of sphingolipid pathway played in t10c12 CLA induced delipidation.  
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Introduction 
Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes [1-4], 
and the trans-10, cis-12 CLA (t10c12 CLA) isomer is capable of causing this response 
[5]. The rates of fatty acid oxidation and lipolysis increased in t10c12 CLA-treated 3T3-
L1 adipocytes [6], while lipolysis increased  and fatty acid biosynthesis decreased in 
t10c12 CLA-treated human adipocytes [7,8]. Molecular responses to t10c12 CLA include 
the activation of AMP-activated protein kinase (AMPK) [9], integrated stress response 
(ISR; [10,11]) or unfolded protein response (UPR; [12]), mitogen-activated protein 
kinase (MAPK) cascades [7], and attenuation of peroxisome proliferator-activated 
receptor γ (PPARγ) protein levels [3]. Treatment with t10c12 CLA requires nuclear 
factor kappa-B (NF-κB) for an inflammatory response [3,4,10,13-15] that includes 
increased prostaglandin biosynthesis in human adipocytes [11], in mouse white adipose 
tissue [16], and 3T3L1 adipocytes [17]. Despite this progress in understanding of the 
pathways involved in the early perception of t10c12 CLA and the complex regulation of 
the subsequent responses, much remains unknown in this process.  
 
AMPK is a central regulator of cellular energy levels that is activated by increases in the 
cellular AMP/ATP ratio, various cellular stresses [18,19], or treatment of adipocytes [9] 
or mice [20] with t10c12 CLA or mixed isomers of CLA. AMPK activation requires 
phosphorylation at Thr172 [21], and two of the target proteins inhibited by 
phosphorylation by AMPK are acetyl-CoA carboxylase (ACC), and fatty acid synthase, 
two key enzymes in fatty acid biosynthesis. Through this and other mechanisms [18,19], 
activated AMPK decreases lipogenesis, increases fatty acid oxidation, and increases 
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lipolysis in adipocytes in vitro and in vivo [22]. Phenformin and metformin are 
structurally related chemicals that can be used to activate AMPK [18,23]. Metformin 
increases TG loss in t10c12 CLA treated adipocytes, while compound C, a potent 
inhibitor of AMPK, attenuates TG loss in this system [9].  
 
PPARγ is a ligand-activated nuclear receptor that regulates lipogenesis and is a key 
regulatory point for controlling inflammation in adipocytes [24]. PPARγ forms a complex 
with nuclear receptor corepressors 1 or 2 (NCoR1 or 2) in the absence of its bound ligand 
[25]. PPARγ transactivation activity is also reduced by phosphorylation at Ser112 by 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal Kinase (JNK), or p38 
MAPKs, and a phosphorylation-dependent sumoylation at K107 [26]. In addition, a non-
genomic role for PPARγ is emerging, as a number of PPARγ-dependent processes are too 
rapid to involve transcriptional responses [27,28]. The critical role of PPARγ in the 
response to t10c12 CLA is demonstrated by the attenuated responses that occur on 
addition of PPARγ agonists [11,29,30].  
 
Protein deacetylation is emerging as an important mechanism for regulating energy 
balance [31,32]. Of the two major classes of histone/protein deacetylases in mammals, 
the NAD-dependent class III sirtuins are structurally and enzymatically distinct from 
those of the zinc-dependent class I/II deacetylases [33]. Within the seven members of the 
sirtuin family, SIRT1 (sirtuin 1) is particularly involved in regulating cell energy 
metabolism, cell stress, and cell fate [34]. SIRT1 directly binds to NCoR1 and directly or 
indirectly to PPARγ to repress PPARγ transactivation activity, inhibit adipogenesis, and 
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increase fat loss in adipocytes [35]. SIRT1 deacetylates liver kinase B1 (LKB1), 
facilitating the ability of LKB1 to phosphorylate AMPK, defining a SIRT1/LKB1/AMPK 
signaling pathway that provides one of the connections between SIRT1 and AMPK for 
regulating energy metabolism [36,37]. SIRT1 also deacetylates NF-κB, thereby 
modulating NF-κB transactivation activity [38,39]. Amongst the chemicals that affect the 
activity of sirtuins, the activator SRT1720 preferentially activates SIRT1 [40], while 
sirtinol and nicotinamide are used as general sirtuin inhibitors that do not inhibit class I/II 
deacetylases [41]. Nicotinamide is a direct product of the sirtuin deacetylation reaction 
that inhibits sirtuin enzymes as a non-competitive product inhibitor [42]. Etomoxir 
indirectly inhibits sirtuin activity as it inhibits fatty acid transport into mitochondria 
which prevents an increase in NAD+, an activator of sirtuin activity [43].  
 
In this study, we analyzed the functional role of SIRT1 in the attenuation of TG levels in 
t10c12 CLA-treated 3T3-L1 adipocytes. Our objectives were to test whether SIRT1 was 
functionally required for robust triglyceride reduction, and whether SIRT1, AMPK, and 
PPARγ cross regulated each other in the response. These experiments were performed 
with activators, inhibitors, or siRNA that affected these pathways and analyzing their 
effects on TG levels, fatty acid metabolism, and post-translational modifications or 
activity levels of SIRT1, AMPK, and PPARγ. 
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Experimental Procedures 
 
Reagents 
Compound C was purchased from Calbiochem (San Diego, CA). Bovine serum albumin 
(BSA, > 99% fat free), dexamethasone, etomoxir, GW9662, insulin, isobutyl-1-
methylxanthine, metformin, nicotinamide, phenformin, and sirtinol were purchased from 
Sigma (St. Louis, MO). Ciglitazone, pioglitazone, rosiglitazone, and troglitazone were 
from Fisher (Pittsburgh, PA). SRT1720 was from Cayman Chemical (Ann Arbor, MI). 
T10c12 CLA (90%, #UC-61-A) was from Nu-Chek Prep, Inc (Elysian, MN). Antibodies 
to acetyl-NF-κB p65 (acetyl K310), p-PPARγ (phospho S112) and negative control 
siRNA were from Abcam (Austin, TX).  Protein A agarose beads, antibodies to β-actin, 
NCoR1, NF-κB p65, PPARγ, SIRT1, anti-goat or anti-rabbit secondary antibodies 
coupled to horseradish peroxidase, and Sirt1 siRNA were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Antibodies to p-AMPK, AMPK, p-ACC, and ACC 
were from Cell Signaling (Beverly, MA).  T7 RNA polymerase (P2077) and rNTPs 
(E6000) were purchased from Promega. SiRNA to lamin A/C, non-target siRNA, and 
DharmaFECT Duo transfection reagent (T-2010-02) were from Dharmacon (Thermo 
Fisher Scientific, Boulder, CO).  
 
3T3-L1 cell culture, differentiation, and chemicals  
Low passage 3T3-L1 fibroblasts [44] were obtained (H. Green, Harvard Medical School) 
and cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) 
containing 10% bovine calf serum (Fisher, Pittsburgh, PA) and differentiated as 
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described [9]. When present, chemicals were dissolved in DMSO, with the exception that 
2 mmol/L metformin and 0.1 mmol/L phenformin were dissolved in water, and were 
added directly to the media at ≤ 0.2% of the final volume in the media. An initial 
chemical concentration was determined from literature values and a range of 
concentrations around this value were then tested for their effects in vivo. From this data, 
the lowest effective concentration was chosen and used at the following concentrations: 5 
µmol/L ciglitazone, 10 µmol/L compound C, 10 µmol/L etomoxir, 10 µmol/L GW9662, 
10 µmol/L nicotinamide, 5 µmol/L pioglitazone, 5 µmol/L rosiglitazone, 10 µmol/L 
sirtinol, 8 µmol/L SRT1720, or 5 µmol/L troglitazone and were added 1 h before adding 
fatty acids. Fatty acids, either linoleic acid or trans-10, cis-12 CLA, were dissolved in 0.1 
M KOH, diluted into fatty acid free (>99%) bovine serum albumin (BSA) in phosphate 
buffered saline at a 1:1 ratio (2 mmol/L BSA: 2 mmol/L fatty acid), pH adjusted to 7.4, 
and added to the cultures containing 4 to 6 d post-differentiated 3T3-L1 adipocytes [9]. 
We used 50 µM t10c12 CLA if assaying chemicals that increased TG loss, but otherwise 
used 100 µM t10c12 CLA. 
 
Fatty acid biosynthesis, oxidation, and lipolysis assays 
Fatty acid biosynthesis was measured in differentiated adipocytes after 24 h of treatment 
by removing the treatment media and incubating the adipocytes in Hanks’ Balanced Salt 
Solution (HBSS; Invitrogen, Carlsbad, CA) containing 37 KBq [14C]-acetate [specific 
activity 2.1 GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA)] for 30 min 
(incorporation was linear for 60 min). Cells were washed in PBS three times, pelleted, 
and then resuspended in 100 µl PBS and 0.1% SDS.  Lipids were extracted in 1 ml of 2:1 
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chloroform:methanol [45] and measured by scintillation counting. Cells briefly exposed 
to 37 KBq [14C]-acetate, followed by immediate washing and extracted as above, were 
used to determine background levels, which were subtracted from sample values. Fatty 
acid oxidation was measured in differentiated adipocytes in 3.5 cm culture plates 12 h 
after starting treatments by adding 37 KBq [14C]-oleic acid [specific activity 2.2 
GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] to the treatment media for 2 h 
and collecting [14C]-CO2 for 1 h in collection jars as reported [46]. For lipolysis assays, 
the TG pool of differentiated adipocytes was labeled by adding 37 KBq [14C]-acetate 
[specific activity 2.1 GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] to the 
media for 4 h, after which time the plates were washed four times with PBS, and specific 
experimental media treatments were initiated. Media (0.1 ml) was collected after 24 h, 
lipids extracted in 1 ml of 2:1 chloroform:methanol [45] and measured by scintillation 
counting. The use of labeled [14C]-acetate and the 2:1 chloroform:methanol extraction 
step considerably reduced non-specific background to 50 DPM, as determined by using 
the above protocol on cells that had been briefly exposed to 37 KBq [14C]-acetate in 
media.  
 
siRNA transfections 
For siRNA transfections, 3T3-L1 adipocytes, 4 to 5 d post differentiation, were 
transfected by siQUEST transfection reagent (Mirus, Madison, WI) or DharmaFECT Duo 
transfection reagent (Dharmacon, Thermo Fisher Scientific, Boulder, CO) as described 
[47]. For siQUEST transfections, concentrations of 2 µl of siQUEST reagent per ml of 
media and 40 nmol/L of siRNA were added 24 h before adding fatty acids. For 
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DharmaFECT Duo transfections, concentrations of 1.4 µl per cm2 of DharmaFECT Duo 
and 80 nmol/L of siRNA were added 24 h before adding fatty acids.  
 
T7 transcription of oligonucleotide templates  
In addition to commercially available siRNAs, we utilized siRNAs derived from 
transcription of oligonucleotide templates with T7 RNA Polymerase as described [48]. 
The siRNA sequences used were: siRNA control sequence: 5’-AAC AGU CGC GUU 
UGC GAC UGG UCU CUU GAA CCA GUC GCA AAC GCG ACU GCC UAU AGU 
GAG UCG UAU UA-3’. LaminA/C siRNA sequence: 5’-AAG GAG GAG CUU GAC 
UUC CAG UCU CUU GAA CUG GAA GUC AAG CUC CUC CCC UAU AGU GAG 
UCG UAU UA-3’. Sirt1 siRNA: 5’-AAG GAG ACU GCG AUG UUA UAA UCU CUU 
GAA UUA UAA CAU CGC AGU CUC CCC UAU AGU GAG UCG UAU UA-3’ 
 
Immunoblot analysis 
Nuclear and cytosolic extracts were isolated using a nuclear extract kit (Active Motif, 
Carlsbad, CA). Equal amounts of proteins from whole cell, nuclear, or cytosolic extracts 
were separated by SDS-PAGE, transferred to Immun-blot PVDF membrane (Bio-Rad 
Laboratories, Hercules, CA), probed with the indicated primary antibodies, and detected 
with secondary antibodies. Enhanced chemiluminescence (Pierce, Rockford, IL) was 
used for detection. Band intensities were determined from digital images from exposures 
in the linear range using software (Quantity One, Biorad, Hercules, CA). All western blot 
analyses were repeated at least three times. 
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Immunoprecipitation 
Immunoprecipitations were performed according to the procedure described [35]. In brief, 
the collected 3T3-L1 adipocytes were sonicated, lysates were centrifuged, and aliquots of 
the supernatants were immunoprecipitated overnight with specific antibody or control 
nonspecific IgG serum. Protein A agarose beads were used to bind the specific or non-
specific antibody complexes, the protein A beads containing bound proteins were washed 
five times, and the bound proteins were eluted in SDS sample buffer for immunoblot 
analysis. 
 
Quantification of TG content 
Cell isolation and TG measurements were performed according to the manufacturer’s 
instructions using TG reagent (T2449; Sigma, St. Louis, MO) and free glycerol reagent 
(F6428; Sigma, St. Louis, MO). TG data are expressed as nmol of TG per mg of protein.    
 
Measurement of MCP-1 and COX2 mRNA 
Total RNA was extracted by TRIzol (Invitrogen) following the manufacturer’s protocol. 
Total RNA (2 μg) was used for cDNA synthesis. Real-time PCR was performed by a 
Bio-Rad iCycler using iQ SYBR Green Supermix reagent (Bio-Rad, Hercules, CA) using 
PCR primers for MCP-1 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [9], 
and COX2 [9]. MCP-1 and COX2 mRNA levels were normalized to GAPDH, which 
showed no significant variation in microarray analyses between linoleic acid and t10c12 
CLA treatments. Experiments were repeated three times, and each sample was analyzed 
using one RNA control and two replicates of each cDNA pool, and the relative amounts 
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of MCP-1, COX2 and GAPDH were calculated using the comparative CT method [49], 
according to the manufacturer’s software (Bio-Rad, Hercules, CA). Cycle numbers were 
used to calculate gene expression levels in the log linear amplification range.  
 
Statistical Analysis 
One or two-way ANOVA was used to analyze the data. Post-hoc pairwise comparisons 
were calculated using Tukey’s test and were considered significant for p≤0.05. All 
analyses were performed using SAS software (SAS, Cary, NC). 
 
Results  
SIRT1 is required for reduced TG levels in t10c12 CLA-treated adipocytes  
We first determined whether increased SIRT1 activity would affect TG levels in t10c12 
CLA-treated differentiating adipocytes. To specifically activate SIRT1, we used 
SRT1720, as this chemical is known to preferentially activate SIRT1 at 8 µM [40]. 
SRT1720, in combination with 50 µM t10c12 CLA, significantly lowered TG to levels 
below those achieved by 50 µM t10c12 CLA alone (Fig. 1A). In contrast, addition of 100 
µM t10c12 CLA in combination with a sirtuin inhibitor, either sirtinol or nicotinamide, 
significantly increased TG levels, relative to those from adipocytes treated with 100 µM 
t10c12 CLA alone (Fig.1. B). Etomoxir, which inhibits sirtuin activity indirectly by 
reducing NAD+ levels via inhibition of mitochondrial fatty acid transport and oxidation 
[43], was also tested. Treatment with etomoxir and t10c12 CLA significantly increased 
TG levels relative to TG levels with t10c12 CLA alone (Fig. 1C). These data supported a 
hypothesis that one or more sirtuins participate in the TG loss response caused by t10c12 
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CLA treatment, and that SIRT1 involvement was likely due to the response to SRT1720, 
a specific SIRT1 activator.  
 
SiRNA was used to reduce SIRT1 expression to confirm the functional involvement of 
SIRT1 in the response to t10c12 CLA. First, to verify that SIRT1 protein levels were 
likely to respond to siRNAi-mediated knockdown of its mRNA levels in t10c12 CLA-
treated adipocytes, the half-life of SIRT1 in cycloheximide treated adipocytes was 
determined to be less than 6 h (Supplemental Figure 1) and that treatment with t10c12 
CLA did not change SIRT1 protein levels (Supplemental Figure 2). We additionally 
verified that our siRNA transfection method could deliver siRNA efficiently enough to 
knockdown protein levels of Lamin A/C (Supplemental Figure 3), a target known to be 
susceptible to siRNA knockdown in adipocytes [47].  
 
A siRNA targeted against SIRT1 mRNA significantly reduced SIRT1 protein levels but 
did not affect β-actin levels, while a control non-target siRNA did not change SIRT1 or 
β-actin amounts (Fig. 1D). In the presence of t10c12 CLA, siRNA knockdown of SIRT1 
in adipocytes produced higher levels of TG levels than those from adipocytes treated with 
a non-target siRNA or reagent only controls (Fig. 1E). In the presence of LA, the siRNA 
SIRT1 treated adipocytes had TG levels that were not significantly different than those 
from adipocytes treated with the control non-target siRNA or reagent (Fig. 1E).  These 
results indicate that siRNA knockdown of SIRT1 attenuated the TG loss caused by 
t10c12 CLA. Taken together with the above inhibitor studies, these results demonstrate 
that inhibition of SIRT1 activity or protein levels significantly interfere with the TG loss 
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caused by t10c12 CLA. Further, the magnitude of the change in TG levels in the inhibitor 
studies (Figures 1b and 1c) and when SIRT1 was knocked down by siRNA (Figure 1e) 
indicates SIRT1 accounts for most or all of the SIRT activity involved in lipid loss in 
t10c12 CLA treated adipocytes.  
 
SIRT1 affects the rates of fatty acid metabolism and the inflammatory response  
The involvement of SIRT1 in t10c12 CLA-mediated changes in the rates of fatty acid 
biosynthesis, oxidation, and lipolysis as well as in the induction of two key inflammatory 
mRNAs was then measured to gain insight into how SIRT1 affected these specific 
pathways. Adipocytes treated with t10c12 CLA alone had a 77% reduction in their rate of 
lipogenesis (Fig. 2A). The combination of t10c12 CLA and sirtinol significantly changed 
this to a 47% reduction in the rate of lipogenesis (Fig. 2A). This result indicated SIRT1 
activity was involved in inhibiting the rate of fatty acid biosynthesis. Adipocytes treated 
with t10c12 CLA exported significantly more radioactively-labeled lipids than LA treated 
cells, but the amount of t10c12 CLA-mediated lipolysis was not significantly affected by 
the sirtuin inhibitor sirtinol (Fig. 2B). The rate of fatty acid oxidation was significantly 
increased in t10c12 CLA-treated adipocytes, and although fatty acid oxidation was less 
when sirtinol was added, this difference was not significant (Fig. 2C). In conclusion, it 
appears the major change in lipid metabolism affected by SIRT1 is the rate of fatty acid 
biosynthesis.   
 
The inflammatory MCP1 and COX2 mRNAs were highly induced by t10c12 CLA 
treatment (Fig. 2D-E). The SIRT1 activator SRT1720, in combination with t10c12 CLA, 
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modestly attenuated the induction of MCP1 to 79% of t10c12 CLA levels, and although 
COX2 mRNA levels were slightly lower, this latter difference was not significant (Fig. 
2D-E).  In contrast, the SIRT1 inhibitors, sirtinol or nicotinamide, when used in 
combination with t10c12 CLA, attenuated the induction of the mRNA of MCP1 relative 
to t10c12 CLA control levels (Fig. 2D). Similarly, sirtinol or nicotinamide, when used in 
combination with t10c12 CLA, attenuated the induction of the mRNA of COX2 relative 
to 10c12 CLA control levels (Fig. 2E). These results indicated SIRT1 partially increased 
the induction of the inflammatory MCP1 and COX2 mRNAs, possibly through its 
inhibition of PPARɣ (see below), which plays an anti-inflammatory role in adipocytes 
[24].   
 
SIRT1 increases AMPK activity 
We next determined whether SIRT1 affected AMPK regulation during the response to 
t10c12 CLA. AMPK activity was measured by the amount of phosphorylation at AMPK 
Thr172 (p-AMPK) and by the amounts of phosphorylated ACC (p-ACC), one of 
AMPK’s key substrates in vivo [50]. We previously demonstrated the t10c12 CLA-
stimulated increase in ACC phosphorylation was less in compound C treated adipocytes, 
supporting the premise that this phosphorylation was mediated by AMPK [9]. Although 
p-AMPK levels were increased by 2 h of treatment with t10c12 CLA, the addition of 
SIRT1 activator SRT1720 or SIRT inhibitors, had no significant effect on the amount of 
p-AMPK or p-ACC produced after 2 h of treatment (Fig. 3A).  However, when used in 
combination with t10c12 CLA for 12 h, SIRT1 activator SRT1720 significantly increased 
p-AMPK or p-ACC levels relative to the amounts present when treated by t10c12 CLA 
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alone (Fig. 3B). Conversely, when used in combination with t10c12 CLA for 12 h, SIRT1 
inhibitors sirtinol or nicotinamide significantly attenuated p-AMPK levels relative to the 
amounts of these proteins in adipocytes treated with t10c12 CLA (Fig. 3B). Similarly, 
when used in combination with t10c12 CLA, siRNA targeting of SIRT1 significantly 
reduced p-AMPK and p-ACC levels relative to the control treatment (Fig. 3C). 
Collectively, these results indicated SIRT1 increased AMPK activity levels after 12 h, but 
not 2 h, of exposure to t10c12 CLA.  
 
A PPARγ agonist or antagonist affects the TG loss response to t10c12 CLA 
The involvement of PPARγ in the TG loss response to t10c12 CLA was then tested 
through addition of a PPARγ antagonist or agonist. The PPARγ antagonist GW9662 
significantly reduced TG levels when used in combination with 50 µM t10c12 CLA 
relative to TG levels in the t10c12 CLA treatment (Fig. 4A). Prior to examining the 
effects of a PPARγ agonist on the response to t10c12 CLA, we first determined that 
troglitazone was the most potent PPARγ agonist amongst a set of four thiazolidinedione 
agonists, as measured by their ability to increase the amount of TG produced in 
differentiating adipocytes (Fig. 4B). Troglitazone significantly attenuated t10c12 CLA‘s 
ability to reduce TG levels, as the combined treatment was not significantly different 
from the LA control (Fig. 4C). These results indicated that, in adipocytes treated with 
t10c12 CLA, a PPARγ antagonist facilitated TG loss while a PPARγ agonist interfered 
with TG loss.  
 
Cross regulation of PPARγ and AMPK in adipocytes treated with t10c12 CLA 
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The cross regulation between PPARγ and AMPK was next determined. When used in 
combination with t10c12 CLA for 12 h, PPARγ antagonist GW9662 significantly 
increased AMPK and ACC phosphorylation levels (Fig. 4D). Conversely, when used in 
combination with t10c12 CLA for 12 h, troglitazone significantly reduced AMPK and 
ACC phosphorylation levels (Fig. 4D). However, when used in combination with t10c12 
CLA for only 2 h there was no significant effect of these chemicals on AMPK or ACC 
phosphorylation levels (Fig. 4D). Therefore, although AMPK activation occurred at 2 h, 
cross regulation by PPARγ was not apparent at 2 h. Phosphorylation of PPARγ increased 
by 140% at 12 h, but not by 2 h, after t10c12 CLA treatment (Fig. 4E-F). When 
compound C was used in combination with t10c12 CLA, the amount of phosphorylated 
PPARγ was reduced relative to the levels when treated by t10c12 CLA. This suggests 
AMPK activity was directly or indirectly involved in the phosphorylation of PPARγ (Fig. 
4F). These results indicated AMPK and PPARγ cross regulated each other in the response 
to t10c12 CLA.  
 
Cross regulation of PPARγ and AMPK also occurs in the absence of t10c12 CLA  
We next determined whether this cross regulation between AMPK and PPARγ was a 
general aspect of these proteins by testing whether this occurred in the absence of t10c12 
CLA. This was done by using two other chemicals to activate AMPK, alone or in 
combination with a PPARγ agonist or antagonist. Phenformin, a strong AMPK activator, 
significantly reduced TG levels to 60% of those present in the untreated control 
adipocytes (Fig. 5A). When phenformin was used in combination with troglitazone, 
significantly more TG was present than in adipocytes treated with phenformin alone (Fig. 
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5A). Metformin, a weaker AMPK activator, only slightly reduced TG levels (Fig. 5B). 
The TG level was further reduced when metformin was used in combination with the 
PPARγ antagonist GW9662 (Fig. 5B). These results indicated that the antagonistic cross 
regulation between AMPK and PPARγ that was observed in the response to t10c12 CLA 
also occurred in phenformin or metformin treated adipocytes in the absence of t10c12 
CLA.    
 
NF-κB is deacetylated by one or more sirtuins in t10c12 CLA treated adipocytes 
The regulation of SIRT1 activity by AMPK and PPARγ was then assessed. A known 
deacetylation target of SIRT1 is Lys310 of the p65 subunit of NF-κB [38].  Therefore, we 
determined whether the p65 subunit of NF-κB changed its acetylation levels in response 
to t10c12 CLA. The acetylation level of the p65 subunit of NF-κB was not significantly 
changed by treatment with t10c12 CLA for 2 h (Fig. 6A). In contrast, the amount of 
acetylated p65 subunit of NF-κB was significantly less in adipocytes treated with t10c12 
CLA for 12 h (Fig. 6B). When t10c12 CLA was used in combination with sirtinol or 
nicotinamide inhibitors of sirtuin activity, the amount of the acetylated p65 subunit of 
NF-κB was significantly higher relative to t10c12 CLA alone (Fig. 6 B). These drug 
inhibition results supported the premise that one or more members of the sirtuin family of 
protein deacetylases were involved in the deacetylation of the p65 subunit of NF-κB. Of 
the seven sirtuin family members, only SIRT1 and SIRT6 have a nuclear localization [51] 
that overlaps with the subcellular localization of acetylated NF-κB. Additionally, of the 
seven sirtuins, only SIRT1 is known to deacetylate the p65 subunit of NF-κB [38]. 
Therefore, these results established that one or more members of the sirtuins, presumably 
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at least SIRT1, were responsible for the deacetylation of the p65 subunit of NF-κB, and 
verified that sirtuin deacetylase activity increased in t10c12 CLA treated adipocytes.  
 
AMPK and PPARγ affect SIRT1 activity 
The involvement of AMPK in regulating SIRT1 activity was then measured using 
compound C, an inhibitor of AMPK. The amount of the acetylated p65 subunit of NF-κB 
significantly increased in a treatment using t10c12 CLA in combination with compound 
C, relative to the acetylation level produced by t10c12 CLA (Fig. 6C). This result 
indicated AMPK was directly or indirectly involved in regulating the SIRT1 
deacetylation response to t10c12 CLA. The PPARγ agonist troglitazone was used to 
determine whether PPARγ affected the levels of acetylation of the p65 subunit of NF-κB. 
When used in combination with t10c12 CLA for 12 h, troglitazone-treated adipocytes 
significantly increased the amount of acetylated p65 subunit of NF-κB relative to the 
t10c12 CLA treatment, suggesting activated PPARγ interferes with SIRT1 deacetylation 
activity (Fig. 6D). Conversely, adipocytes treated with t10c12 CLA and the PPARγ 
antagonist GW9662 significantly reduced the amounts of acetylated p65 subunit of NF-
κB relative to the t10c12 CLA treatment, suggesting inhibition of PPARγ increases 
SIRT1 deacetylation activity (Fig. 6D). Collectively, these results indicated that AMPK 
positively regulated, and PPARγ negatively regulated, SIRT1 activity in vivo, as 
measured by the deacetylation of the p65 subunit of NF-κB.  
 
SIRT1 increases its binding to PPARγ and NCoR1 in t10c12 CLA treated adipocytes  
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A possible mechanism for cross regulation of SIRT1 and PPARγ is through participation 
within a common protein complex [35]. Using co-immunoprecipitation with a SIRT1 
antibody, we observed that t10c12 CLA treatment resulted in a significant increase in the 
amount of a SIRT1/PPARγ protein complex relative to the amount of this complex in the 
LA control, despite an overall reduction in PPARγ protein levels in t10c12 CLA treated 
cells (Fig. 7). Again using the same co-immunoprecipitation method, we observed that 
the amount of a protein complex containing SIRT1 and NCoR1 also significantly 
increased in the presence of t10c12 CLA (Fig. 7). These results demonstrated that there 
was increased binding of SIRT1 to PPARγ and NCoR1 in t10c12 CLA treated adipocytes.  
 
Discussion  
Here we demonstrated that SIRT1 activity was functionally involved in the TG loss 
response that occurred in t10c12 CLA-treated 3T3-L1 adipocytes. Our chemical inhibitor 
and activator studies indicated SIRT1 facilitated TG loss, as did AMPK, while PPARγ 
stimulated TG synthesis (summarized in Figure 8). Our assays of protein activities, 
modifications, and interactions supported this functional data and provided molecular 
evidence of cross regulation between SIRT1, AMPK and PPARγ in the response to 
t10c12 CLA. As discussed below, each of these proteins directly or indirectly affected the 
activity of the others.  
 
In order to evaluate the effects of SIRT1 on specific pathways in lipid metabolism, we 
first established the effects of t10c12 CLA on lipid metabolism in our 3T3-L1 adipocyte 
system. The decrease in TG levels in t10c12 CLA-treated adipocytes was caused by a 
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combination of reduced fatty acid biosynthesis, increased lipolysis, and increased fatty 
acid oxidation. Our finding that t10c12 CLA-treated adipocytes have increased p-AMPK 
levels and increased lipolysis and fatty acid oxidation is consistent with a report that 
activated AMPK increases lipolysis and fatty acid oxidation [22]. Our results were also 
consistent with the increased lipolysis and fatty acid oxidation, but not the increased fatty 
acid biosynthesis, reported in t10c12 CLA-treated 3T3-L1 adipocytes [6]. The latter 
difference may reflect differences in the specific cell cultures. The reduction in the rate of 
fatty acid synthesis was consistent with the reduced transcript levels of lipid biosynthetic 
enzymes such as ACC1, ACC2, and fatty acid synthase in mice and 3T3-L1 adipocytes 
[10,15], possibly mediated by AMPK’s ability to phosphorylate and inhibit SREBP1, a 
key regulatory factor of these genes [52]. Further, the reduction in the rate of fatty acid 
synthesis was consistent with increased phosphorylation of ACC, which inhibits ACC 
(both ACC-1 and ACC-2 isoforms) and thereby inhibits production of malonyl-CoA. 
Reduced concentrations of malonyl-CoA should reduce the rate of fatty acid biosynthesis 
and increase the rate of fatty acid oxidation, as attenuated levels of malonyl-CoA no 
longer inhibit carnitine palmitoyltransferase-mediated transport of fatty acids into 
mitochondria for β-oxidation [18,19,50]. Fatty acid synthesis was also likely reduced by 
AMPK’s ability to phosphorylate and inhibit fatty acid synthase [18,19]. Our studies 
indicated that SIRT1 primarily affected the rate of fatty acid biosynthesis as inhibition of 
SIRT1 did not significantly affect the rate of lipolysis or fatty acid oxidation in the 
response to t10c12 CLA. Whether SIRT1 regulates fatty acid biosynthesis primarily via 
differential modulation of the activities of AMPK and PPARγ or additionally through 
direct deacetylation of metabolic enzymes [53] requires additional research.  
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Our results strongly support an increase in SIRT1 deacetylase activity occurs in vivo in 
t10c12 CLA treated adipocytes. We used the acetylation levels of Lys310 of the p65 
subunit of NF-κB as an indicator of SIRT1 deacetylase activity in vivo. NF-κB/p65 had 
reduced amounts of acetylation at Lys310 in t10c12 CLA-treated adipocytes, indicating 
increased deacetylase activity was occurring.  However, in principle Lys310 of p65/NF-
κB can be deacetylated by both class I/II or sirtuin deacetylases [38]. Results with the 
sirtuin-specific inhibitors indicated the majority of NF-κB/p65 deacetylation was 
accomplished by the sirtuin class of deacetylases. Of the seven sirtuin family members, 
only SIRT1 and SIRT6 have the nuclear localization [51] needed to deacetylate nuclear-
localized NF-κB. Of these two candidates, SIRT1 is likely to be involved as SIRT1 
physically binds to the p65 subunit of NF-κB and deacetylates it at Lys310 in human lung 
cells [38]. Further, our siRNA knockdown of SIRT1 indicates it is the major contributor 
to SIRT function in the t10c12 CLA response (Figure 1E). Therefore, our results strongly 
support an increase in the deacetylase activity of SIRT1 in t10c12 CLA-treated 
adipocytes, without ruling out minor contributions from other sirtuins.  
 
The functional consequences of alterations in SIRT1, AMPK, and PPARγ activities 
suggested there was cross-regulation between these proteins (summarized in Figure 8). 
Therefore, evidence for changes in protein modifications and/or activity was investigated. 
In the case of SIRT1 affecting AMPK, an activator of SIRT1 increased AMPK activity, 
while inhibitors of SIRT1 reduced AMPK activity in t10c12 CLA-treated adipocytes. A 
possible pathway connecting SIRT1 to AMPK is a SIRT1/LKB1/AMPK axis by which 
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SIRT1 can affect AMPK activity via deacetylation of protein kinase LKB1, which 
increases LKB1’s ability to activate AMPK by phosphorylation [36,37]. In the case of 
SIRT1 affecting PPARγ, we found treatment with t10c12 CLA caused more SIRT1 to 
bind to PPARγ and NCoR1. This is likely to inhibit PPARγ activity as the increased 
binding of SIRT1 to PPARγ and NCoR1 that occurred during fasting reduced PPARγ 
transcriptional activity [35]. Reduced PPARγ activity is consistent with the reduced 
transcription of lipogenic genes observed in t10c12 CLA treated adipocytes [10,13,15]. 
These results support a conclusion that SIRT1 stimulated AMPK activity and attenuated 
PPARγ activity in t10c12 CLA treated adipocytes. 
 
In the case of AMPK affecting SIRT1, inhibition of AMPK with compound C reduced 
SIRT1 activity as measured by the deacetylation of p65/NF-κB. The mechanism is 
unclear but could include AMPK-mediated changes in fatty acid oxidation which affect 
the NAD+/NADH ratio that affects SIRT1 activity [43]. In the case of AMPK affecting 
PPARγ, AMPK was directly or indirectly responsible for the increased phosphorylated at 
Ser112 of PPARγ in t10c12 CLA treated adipocytes [29], as this effect was attenuated by 
the AMPK inhibitor compound C. Phosphorylation of PPARγ at Ser112 facilitates its 
SUMOylation at K107, and thereby decreasing its transactivation activity [26]. These 
results support a conclusion that AMPK stimulated SIRT1 activity and attenuated PPARγ 
activity in t10c12 CLA treated adipocytes. 
 
In the case of PPARγ affecting AMPK and SIRT1, troglitazone, a PPARγ agonist, 
reduced the activities of AMPK and SIRT1. Conversely, GW9662, an antagonist of 
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PPARγ, increased the activities of AMPK and SIRT1. These results demonstrate that 
PPARγ has a repressive effect on the activities of these proteins, which is consistent with 
the opposing roles of PPARγ’s in stimulating lipid biosynthesis and the catabolic energy-
generating roles of AMPK and SIRT1 [30,54]. The mechanisms of how PPARγ affects 
AMPK and SIRT1 are unclear, despite the physical interaction between SIRT1 and 
PPARγ [35,55]. Although the mechanisms are unclear, PPARγ affected the activity levels 
of SIRT1 and AMPK without changing the total amounts of these proteins in the 
response to t10c12 CLA. This suggests that PPARγ achieved these effects via a non-
transcriptional mechanism. As such, our results support an emerging role for PPARγ in 
regulating non-genomic processes [27,28].  
 
We also used AMPK activators in addition to t10c12 CLA to manipulate AMPK activity 
and explore whether cross regulation of AMPK and PPARγ occurred in the absence of 
t10c12 CLA (summarized in Figure 8).  Phenformin, a potent AMPK activator, caused a 
TG loss similar to that caused by t10c12 CLA treatment. Troglitazone, the most potent 
PPARγ agonist in our 3T3-L1 adipocyte system, attenuated the TG loss caused by 
phenformin. Conversely, GW9662, a PPARγ antagonist, increased the amount of TG loss 
when used with metformin, a moderate AMPK activator. This latter finding supports a 
hypothesis that both AMPK activation [9] and reduced PPARγ activity [3] are important 
for reducing TG levels. Taken together, these results support a hypothesis that cross 
regulation between AMPK and PPARγ also occurs in the absence of t10c12 CLA, and is 
therefore likely to generally occur between these proteins in adipocytes.  
 
51 
 
Both AMPK and SIRT1 play major roles in regulating cellular energy homeostasis and in 
response to caloric restriction [54,56,57]. The involvement of AMPK and SIRT1 in the 
response to t10c12 CLA is consistent with an overall similarity to cellular energy 
restriction. This is supported by the strong similarity of the whole genome transcriptional 
response of adipocytes treated with t10c12 CLA to the response caused by metformin [9], 
which affects the cellular AMP/ATP ratio [58,59].  Similarly, phenformin, which also 
affects the cellular AMP/ATP ratio, caused TG losses similar to those caused by t10c12 
CLA and caused a whole genome transcriptional response similar to that of t10c12 CLA-
treated adipocytes [17]. Our results indicated SIRT1 activation and cross regulation of 
AMPK occurred at 12 h but not as early as 2 h, while AMPK was activated at 2 h or 
earlier [9]. This is consistent with the suggestion that AMPK  activation is a critical early 
event [9]. The signaling pathways used by t10c12 CLA to activate AMPK remain 
unknown. 
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Figure Legends 
 
 
 
 
 
 
 
 
 
 
Figure 1. SIRT activity affects TG levels in t10c12 CLA treated 3T3-L1 adipocytes.   
a-c Triglyceride (TG) levels were measured in differentiating adipocytes after incubation 
with LA (L) or t10c12 CLA (C), with or without the SIRT1 activator SRT1720 (SRT), or 
the sirtuin inhibitors sirtinol (SOL), nicotinamide (NAM), or etomoxir (ETO) for 24 h. d 
Immunoblot analysis of whole cell extracts for the amount of SIRT1 and β-actin proteins 
after exposure to 80 nmol/L of control siRNA (siCON), or siRNA against SIRT1 (siSirt1), 
or transfection reagent only. Duplicate loadings of each sample were analyzed and the 
lanes marked by 1/3 have one third of the indicated samples loaded.  e Triglyceride (TG) 
amounts after treatments as in d. Each bar in panels a-c and e represents the mean + SEM 
(n=3), and is representative of three independent experiments. Means not sharing a 
common letter differ, P   0.05. Panel d is a representative blot of three independent 
experiments. 
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Figure 2. SIRT1 affects fatty acid metabolism and inflammatory mRNA levels.    
a-c The effects of 100 µmol/L of t10c12 CLA, with or without the sirtuin inhibitor 
sirtinol (SOL), on the rates of fatty acid metabolism were measured by radioactive tracers 
(disintegrations per minute: dpm) as follows: a fatty acid biosynthesis by incorporation of 
[1-14C]-acetate; b lipolysis by the release of lipids previously labeled with [1-14C]-acetate; 
c fatty acid oxidation by the release of [14C]-CO2 from lipids previously labeled with [1-
14C]-oleate. d-e The effects of the SIRT1 activator SRT1720 (SRT), or the sirtuin 
inhibitors sirtinol (SOL) or nicotinamide (NAM) on RNA levels in LA or t10c12 CLA 
treated adipocytes were analyzed for MCP-1 and COX2 relative to GAPDH by reverse 
transcription and quantitative PCR. The relative amounts of MCP-1 and COX2 mRNA 
are shown as bar graphs.  Each bar in panels a-e represents the mean + SEM (n=3 for a-b 
or n=2 for c-e), and is representative of three independent experiments.  Means not 
sharing a common letter differ, P   0.05. 
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Figure 3. SIRT1 affects ACC and AMPK phosphorylation levels after t10c12 CLA 
treatment.  
Differentiated 3T3-L1 adipocytes were incubated with 100 µmol/L LA (L) or t10c12 
CLA (C): a with or without SIRT1 activator SRT1720 (SRT), or sirtuin inhibitors sirtinol 
(SOL) or nicotinamide (NAM) for 2 or b 12 h; or c with 40 nmol/L of SIRT1 siRNA 
(siSIRT1) or control siRNA (siCON). Representative western blots indicate the proteins 
detected in cytosolic extracts with antibodies to p-ACC (p-Ser79), or total ACC, p-
AMPK (p-Thr172), or total AMPK. Each bar in panels a-c represents the mean + SEM 
(n=3) of the ratio of the phosphorylated to total form of each protein (phospho/total) for 
three independent experiments. Means for p-AMPK/AMPK (a-e) or p-ACC/ACC (u-x) 
not sharing a common letter differ, P   0.05.  
55 
 
 
Figure 4. PPARγ antagonists and agonists affect TG levels and modulate p-AMPK 
activity levels in t10c12 CLA treated 3T3-L1 adipocytes.  
a Differentiated adipocytes were incubated with 50 µmol/L LA (L) or t10c12 CLA (C) 
with or without PPARγ antagonist GW9662 (9662) for 24 h and TG levels were 
measured.  b Differentiating adipocytes were treated with either control media (0), 
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troglitazone (Tro), ciglitazone (C), rosiglitazone (R), or pioglitazone (P) to determine 
which PPARγ agonist was most effective for increasing TG levels. c Differentiated 3T3-
L1 adipocytes were incubated with 100 µmol/L LA or t10c12 CLA, with or without 
PPARγ agonist troglitazone (Tro), and TG levels were measured after 24 h. d Adipocytes 
were treated as in a or c for 2 or 12 h using 100 µmol/L LA or t10c12 CLA, and 
representative western blots of cytosolic extracts indicate the proteins detected with 
antibodies to p-ACC (p-Ser79), total ACC, p-AMPK (p-Thr172), or total AMPK. The 
ratio of the phosphorylated to total form of each protein (phospho/total) is shown in the 
bar graphs. e-f The amount of phosphorylated or total PPARγ in nuclear extracts was 
measured after 2 or 12 h of treatment with 100 µmol/L LA or t10c12 CLA, and with or 
without compound C (Comp. C) at 12 h. The ratio of the amount of phosphorylated to 
total PPARγ is shown in the bar graphs. Each bar in panels a-f represents the mean + 
SEM (n=3), and is representative of three independent experiments (a-c) or is the mean 
of three independent experiments (d-f). Means within each data type (a-e or u-x) not 
sharing a common letter differ, P   0.05. 
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Figure 5. PPARγ agonists or antagonists affect the TG loss caused by AMPK activators 
without t10c12 CLA being present.  
a Differentiated 3T3-L1 adipocytes were incubated with or without 0.1 mmol/L 
phenformin (Phen), with or without PPARγ agonist troglitazone (Tro), and TG levels 
were measured after 24 h. b TG levels were measured in differentiated 3T3-L1 
adipocytes in media lacking or containing 2 mmol/L metformin (Met), with or without 
PPARγ antagonist GW9662 (9662) for 24 h. Each bar represents the mean + SEM (n=3), 
and is representative of three independent experiments. Means not sharing a common 
letter differ, P   0.05.  
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Figure 6. SIRT1, AMPK and PPARγ affect the t10c12 CLA-dependent decrease in the 
amount of acetylated NF-κB.  
The amount of acetylation on the p65 subunit of NF-κB or the total amount of p65 in 
nuclear extracts was detected by immunoblot analysis with antibodies specific for 
acetylated p65 or total p65. The ratio of the acetylated to total p65 is shown in the bar 
graphs (Acetyl-p65/p65). a-c Differentiated 3T3-L1 adipocytes were incubated with 100 
µmol/L LA (L) or t10c12 CLA (C) a for 2 h, or b for 12 h, with or without sirtuin 
inhibitors sirtinol (SOL) or nicotinamide (NAM), or c with or without AMPK inhibitor 
compound C (Comp.C).  d The effects of PPARγ agonist troglitazone (Tro) or PPARγ 
antagonist GW9662 (9662), in combination with LA or t10c12 CLA, on the acetylation 
of the p65 subunit of NF-κB was measured. Each bar in panels a-d represents the mean + 
SEM (n=3) of three independent experiments.  Means not sharing a common letter differ, 
P   0.05. 
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Figure 7. Treatment with t10c12 CLA increases the interaction of SIRT1 with PPARγ or 
NCoR1.  
Differentiated 3T3-L1 adipocytes were incubated with 100 µmol/L LA (L) or t10c12 
CLA (C) for 12 h, and a portion of the nuclear extracts were immunoprecipitated with 
antibody to SIRT1 (IP: SIRT1). Representative immunoblots (IB) indicate the proteins 
detected from the nuclear extracts (5% input) or when the immunoprecipitated proteins 
were probed with antibodies to SIRT1, PPARγ, or NCoR1. Each bar represents the mean 
+ SEM (n=3) of three independent experiments. Means within each data type not sharing 
a common letter differ, P   0.05. 
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Figure 8. Summary diagram for proposed effects of AMPK, SIRT1, PPARγ, and their 
activators or inhibitors in 3T3-L1 adipocytes.  
AMPK and SIRT1 impair lipid synthesis and PPARγ activity (red lines with stop bars), 
and stimulate each other (blue arrows). PPARγ impairs AMPK and SIRT1 activity and 
stimulates lipid synthesis. The activating (blue arrows) or inhibiting (red line with stop 
bar) effects of the different chemical activators and inhibitors are also shown.  
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Abstract 
Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes. This 
outcome is achieved through a variety of biological responses including increased energy 
expenditure and fatty acid oxidation, increased inflammation, repression of fatty acid 
biosynthesis, attenuated glucose transport, and apoptosis. In the current study profiling of 
261 metabolites was conducted to gain new insights into the biological pathways 
responding to CLA in 3T3-L1 adipocytes [Appendix].  Sphingonine, sphingosine, and 
ceramide levels were observed to be highly elevated in CLA treated adipocytes. 
Exogenous chemicals that increase endogenous ceramide levels decreased lipid levels in 
adipocytes, and activated AMP-activated protein kinase as well as nuclear factor kappa-B, 
both of which are normally activated in CLA treated adipocytes. Concurrent inhibition of 
de novo ceramide biosynthesis and entry from existing sphingoglipid pools attenuated the 
lipid lowering and apoptotic effects normally associated with responses to CLA. Our 
results indicate ceramides are an important component of the lipid lowering response in 
CLA treated adipocytes.  
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Introduction 
Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes [1-4], 
and the trans-10, cis-12 isomer of CLA (t10c12 CLA) is capable of causing this response 
[5]. Molecular responses to t10c12 CLA treatment include the activation of AMP-
activated protein kinase (AMPK) [6], Sirtuin 1 [7], and attenuation of peroxisome 
proliferator-activated receptor γ (PPARγ) protein levels [3]. Treatment with t10c12 CLA 
requires nuclear factor kappa-B (NF-κB) for an inflammatory response [3,4,8-11] that 
includes increased prostaglandin biosynthesis in human adipocytes [12], in mouse white 
adipose tissue [13], and 3T3-L1 adipocytes [14]. Despite this progress in understanding 
the pathways involved in the early perception of t10c12 CLA and the complex regulation 
of the subsequent responses, much remains unknown in this process.  
  
Sphingolipids are a complex class of lipids containing the sphingoid backbones of 
sphinganine (dihydrosphingosine) and sphingosine. Attaching sphinganine or sphingosine 
to a fatty acid via an amide linkage forms ceramide, the simplest sphingolipid that is the 
starting point for more complex shingomyelins, cerebrosides, and gangliosides [15]. 
Sphingolipids have structural roles in lipid membranes and can serve as sources of 
signaling molecules as well. Signaling pathways affected by sphingolipids or molecules 
derived from them, include apoptosis, inflammation, mitochondrial function, metabolism, 
and obesity [16,17].  
  
The role of sphinoglipids in adipocytes and obesity is still emerging. A study of 
genetically obese mice (ob/ob) and high-fat diet-induced obese mice found inhibiting 
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ceramide de novo synthesis attenuated obesity symptoms, facilitating weight reduction, 
better energy metabolism, and improved insulin sensitivity [18]. In 3T3-L1 adipocytes, 
ceramide levels decreased as pre-adipocytes differentiated into adipocytes, and increased 
when adipocytes were treated with epigallocatechin gallate, which reduced adipocyte fat 
content [19].  
  
In this study we performed metabolic profiling of t10c12 CLA treated adipocytes, and 
identified sphinganine and sphingosine as being elevated. The role of the ceramide 
pathway was then further characterized to determine its functional contribution to 
lowering of fat content in t10c12 CLA treated adipocytes. Elevated ceramide levels were 
necessary for efficient fat loss in t10c12 CLA treated adipocytes, and chemicals that 
increased ceramide levels were sufficient to cause efficient fat loss when added to 
adipocyte cultures.  
 
Material and methods 
Reagents. Insulin, Isobutyl-methylxanthine, Dexamethasone, Bovine serum, Calf serum, 
N-Acetyl-D-sphingosine (C2 ceramide), monoclonal anti-ceramide antibody, Myriocin, 
Fumonisin B1 and SKI-II were from Sigma (St. Louis, MO). Ampk inhibitor Compound 
C was from Calbiochem (San Diego, CA). Antibodies to β-actin, Sphingosine-1-
phosphate phosphatase 1(Sppase) and Serine palmitoyltransferase (SPTLC) were from 
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to p-AMPK and AMPK were 
purchased from Cell Signaling (Beverly, MA). T7 RNA polymerase, RNase-Free DNase 
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I and rNTPs were purchased from Promega (Madison, WI). DharmaFECT Duo 
transfection reagent was from Dharmacon (Thermo Fisher Scientific, Boulder, CO).  
 
3T3-L1 cell culture and differentiation. 3T3-L1 fibroblasts[20] were obtained and 
cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) 
containing 10% bovine calf serum (Fisher, Pittsburgh, PA) and differentiated as 
described [7]. Chemicals were dissolved in DMSO, with the exception that C2-ceramide 
was dissolved in ethanol. The lowest effective chemical concentrations were chosen by 
testing a range of initial concentration and were as follows: 20 µmol/L Fumonisin B1, 50 
µmol/L Myriocin, 10 µgl/mL SKI-II, 30 µmol/L C2-ceramide, and were added 1 h before 
adding fatty acids. Chemicals were added directly to the media at ≤0.2% of the final 
volume in the media.  
 
Fatty acid preparation. Fatty acids (>99%, Nu-check Prep, Elysian, MN), either linoleic 
acid (LA) or trans-10, cis-12 conjugated linoleic acid (CLA), were dissolved in 0.1 M 
KOH, diluted into fatty acid free (>99%) bovine serum albumin (BSA) in phosphate 
buffered saline at a 1:1 ratio (2 mmol/L BSA: 2 mmol/L fatty acid), pH adjusted to 7.4, 
and added to the cultures containing 4 to 6 d post-differentiated 3T3-L1 adipocytes[7]. 
All media contained 100,000U/L penicillin and 172µmol/L streptomycin (Invitrogen, 
Carlsbad, CA) . 50 µM t10c12 CLA was used if assaying chemicals that increased TG 
loss as this facilitated observing TG loss, but otherwise 100 µM t10c12 CLA was used. 
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Metabolic profiling. Metabolite profiling of 3T3-L1 adipocytes was performed by 
Metabolon (Durham, NC). Six replicates of 3T3-L1 adipocytes, treated with 100 µM LA 
or t10c12 CLA for 0.5 h or 12 h, were collected, frozen at -80 ◦C for later analysis. 
Samples were solvent extracted and analyzed by GC/MS and LC/MS or LC/MS/MS 
platforms for 261 metabolites. Compounds were identified by known standards or prior 
characterizations of metabolite libraries. Welch’s two–sample t-tests were used to 
identify biochemicals that differed significantly between conjugated linoleic acid and 
linoleic acid treatments.  
 
RNA interference. 3T3-L1 adipocytes, 4 to 5 days post differentiation, were transfected 
by DharmaFECT Duo transfection reagent as described [21]. The final transfection 
reagent concentration was 1.4µl/cm2. DharmaFECT Duo and 100nmol/L shRNA were 
added 24h before adding fatty acids. For drug and shRNA combination assays, drugs 
were subsequently added to media 1h before transfection.  
 
shRNA prepration. Initial sequence against targets were obtained from literature [22,23] 
or online tools (http://sirna.wi.mit.edu/,  http://www.thermoscientificbio.com/design-
center/?redirect=true). 5 potential sequences for each target were chosen and prepared as 
described [24]. In brief, shRNA sequences were synthesized using the T7 polymerase 
(Promega, Madison, WI) templates and purified by 12-20% denaturing polyacrylamide 
gel. The shRNA sequences used were: scramble (sh-Non): 5′-AAC AGU CGC GUU 
UGC GAC UGG UCU CUU GAA CCA GUC GCA AAC GCG ACU GCC UAU AGU 
GAG UCG UAU UA-3′; Sphingosine-1-phosphate phosphatase 1 (sh-Sppase): 5′-AAU 
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CAU CAA GCU GGA GGU CUU CUU CUC UUG AAA GAA GAC CUC CAG CUU 
GAU GAC CUA UAG UGA GUC GUA UUA-3′; or Serine palmitoyltransferase 1 (sh-
Sptlc): 5′-AAG CCA UCA UUU ACU CGU AUG UCU CUU GCA CAU ACG AGU 
AAA UGA UGG CCC UAU AGU GAG UCG UAU UA-3′. 
 
Western blot. Nuclear and cytosolic extracts were isolated using a nuclear extract kit 
(Active Motif, Carlsbad, CA). Equal amounts of  proteins were separated by SDS-PAGE, 
transferred to Immun-blot PVDF membrane (Bio-Rad Laboratories, Hercules, CA), 
probed with the indicated primary antibodies, and detected with secondary antibodies. 
Enhanced chemiluminescence (Pierce, Rockford, IL) was used for detection. Band 
intensities were determined from digital images from exposures in the linear range using 
software (Quantity One, Biorad, Hercules, CA). All western blot analyses were repeated 
at least three times. 
 
Ceramide assay.  Immunodot blots for ceramide levels were performed as described 
with modifications [25-27]. Equal amount of cells (1.5x105) in 12-well plates from each 
treatment were collected by spinning down at 100xg for 5 min. Cells were resuspended in 
500µl ice-cold acidic methanol (acetic acid:  methanol 1:50). Lipids were extracted by 
addition of 500µl chloroform and 500µl H2O. The organic lower-phase was collected and 
evaporated with nitrogen gas. After adding 100 µl of chloroform/methanol (2:1, v/v) to 
each tube, 2µl of of each sample was spotted on PVDF membrane and allowed to dry for 
30 min. The PVDF membrane was blocked with 5% dry milk in PBS at room 
temperature for 1 hour, and standard immunoblot procedures followed to detect ceramide 
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levels using a monoclonal antibody that detects ceramides (Sigma, Saint Louis, MO, 
USA).   
 
Quantification of TG content. Cell isolation and TG measurements were performed 
according 
to the manufacturer’s instructions using TG reagent (T2449; Sigma, St. Louis, MO) and 
free glycerol reagent (F6428; Sigma, St. Louis, MO). TG data are expressed as nmol of 
TG per µg of DNA.  
 
Quantification of DNA content. DNA content assay was performed by Hoechst (33342 
sigma B2261) stain according to the manufacturer’s instructions (Thermo Scientific, 
Pittsburg, PA). 
 
Statistical Analysis.  One or two-way ANOVA was used to analyze the data. Posthoc 
pairwise comparisons were calculated using Tukey’s test and were considered significant 
for p ≤ 0.05. All analyses were performed using SAS software (SAS, Cary, NC). 
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Results 
Metabolite profiling of t10c12 CLA treated 3T3-L1 adipocytes  
A metabolic profiling analysis of 3T3-L1 adipocytes treated with either 100 µM LA or 
t10c12 CLA for 0.5 h or 12 h was conducted for the purpose of identifying early changes 
in metabolites in these cells. A total of 261 metabolites were surveyed in this analysis 
(Supplemental Table 1). At 0.5 h, the main change was the large increase in t10c12 CLA 
relative to the LA controls, indicating rapid uptake of t10c12 CLA by the adipocytes. At 
12 h, there were changes in various lipid levels, consistent with the ability of t10c12 CLA 
to perturb lipid metabolism (Supplemental Table 1). However, the most striking change 
and focus of the present study was a 9.8 fold increase in sphinganine and a 3.6 fold 
increase in sphingosine (Table 1). This indicates the sphingolipid pathway is highly 
elevated 12 h after adding t10c12 CLA. Sphinganine is early in the biosynthetic pathway 
for ceramides, while sphingosine is derived from ceramides (Figure 1). Ceramides were 
not measured in this metabolite profiling analysis.   
 
Ceramide levels increase in t10c12 CLA treated 3T3-L1 adipocytes and cause 
triglyceride reductions. 
An immunoblot analysis of ceramide levels confirmed that they are elevated in 
adipocytes treated with 50 µM t10c12 CLA, and are present at higher levels if treated 
with 100 µM t10c12 CLA (Figure 2A). Thus, t10c12 CLA strongly increases 
ceramide/sphingolipid pools in adipoctyes. To test the hypothesis that ceramides and/or 
sphinoglipids are functionally involved in t10c12 CLA-mediated TG loss in adipocytes, 
we tested two chemicals that enhance this pathway. C2 ceramide is a short chain 
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ceramide that can mimic some ceramide responses  [28]. SKI-II (also known as 
sphingosine kinase inhibitor 2) is a chemical that inhibits sphingosine kinase, which 
normally depletes the sphingosine pool by producing sphingosine-1-phosphate (S1P, 
Figure 1). Addition of 30 µM C2 ceramide to adipocytes results in strong reductions in 
TG levels in the presence of LA, without further reductions in TG levels in the presence 
of 50 µM t10c12 CLA (Figure 2B; Note this study uses 50 µM t10c12 CLA treatments 
when looking for effects that lower TG levels. This is because 100 µM t10c12 CLA 
efficiently depletes TG levels, making further reductions difficult to measure. Conversely, 
we use 100 µM t10c12 CLA when analyzing effects that increase TG levels as having 
lower TG levels as a reference point provides a larger range of measurable TG increases).  
 
Addition of SKI-II, which is expected to increase ceramide and sphingosine levels by 
inhibiting production of S1P from sphingosine (Figure 1), gives a similar result: strong 
loss of TGs occurs in the presence of SKI-II in LA or t10c12 CLA treated adipocytes 
(Figure 2B). Measurement of ceramide levels in these treated adipocytes indicates that 
addition of C2 ceramide or SKI-II raised endogenous ceramide levels in LA or t10c12 
CLA treated adipocytes (Figure 2A). Note this immunological assay does not detect C2 
ceramide (Supplemental Figure 1), indicating exogenous C2 ceramide increases 
endogenous ceramide levels.  These results suggest that increased 
ceramides/sphingolipids can mediate TG loss in the absence of t10c12 CLA (Figure 2B). 
Further, there is not an additive effect on lowering TG levels when these chemicals are 
combined with 50 µM t10c12 CLA.  
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A remaining question is whether ceramide/sphinolipid pathways are required for TG loss 
in t10c12 CLA treated adipocytes. The diversity of sphingolipid pools and the 
bioconversions between these pools makes this a difficult question to answer. For 
example, adding fumonisin B1 or myriocin, both inhibitors of ceramide biosynthesis 
(Figure 1), had little effect on the TG levels in the presence of 100 µM t10c12 CLA 
(Figure 2C). Analysis of ceramide levels in adipocytes treated with 100 µM t10c12 CLA 
and these chemicals indicates that ceramide levels remained high in these cells despite 
the presence of these inhibitors (Figure 2D). This result suggests the ceramides are likely 
to be derived from de novo biosynthesis and established pools within these adipocytes.  
 
To gain more experimental control over inhibiting ceramide production, we developed 
short hairpin RNA (shRNA) knockdowns for serine palmitoyltransferase 1 (SPT1) and 
S1P  phosphatase (S1PP). SPT1 catalyzes the initial step in ceramide biosynthesis and 
S1PP produces sphingosine from existing pools of S1P (Figure 1). Efficient shRNA 
knockdown of SPT1 was achieved (Figure 3A), but this knockdown consistently resulted 
in increased TG levels in both LA and t10c12 CLA treated adipocytes (Figure 3B), 
making interpretation difficult. ShRNA knockdown of S1PP was efficient (Figure 3C), 
but did not affect TG levels in t10c12 CLA treated adipocytes (Figure 3B). When 
ceramide levels were measured for the SPT1 and S1PP shRNA knockdowns in t10c12 
CLA treated adipocytes, they were still quite high, indicating inhibition of either one of 
these enzymes was not sufficient to diminish ceramide levels (Figure 3D).  
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In order to investigate the effects of inhibiting production of ceramides concurrently from 
both the biosynthetic and S1P entry points into the pathway, combinations of shRNA 
knockdowns of S1PP and chemical inhibitors were explored. A combination of shRNA 
against S1PP and myriocin, a SPT inhibitor, is expected to inhibit both de novo 
biosynthesis of ceramides and their production from S1P (Figure 1). This combination 
was sufficient to strongly diminish ceramide levels in 100 µM t10c12 CLA treated 
adipocytes (Figure 4A). Further, this combination had higher TG levels in the presence of 
100 µM t10c12 CLA, relative to 100 µM t10c12 CLA alone, indicating it was effective in 
attenuating the ability of t10c12 CLA to cause TG loss (Figure 4B).  
 
A similar analysis was performed using a combination of shRNA against S1PP and 
fumonisin B1. Fumonisin B1 is an inhibitor of sphinganine N-acyltransferase (Figure 1), 
and thereby should inhibit ceramide biosynthesis. In combination with a shRNA 
knockdown S1PP, this should block both biosynthesis of ceramide and its generation 
from S1P (Figure 1). This combination was sufficient to strongly diminish ceramide 
levels in 100 µM t10c12 CLA treated adipocytes (Figure 4A). However, although this 
treatment had a higher ratio of TGCLA/TGLA than the control, part of this effect of the 
combination treatment was due to the lower TG levels in the LA treated sample (Figure 
4B). As this result is difficult to interpret, our analysis relies primarily on the above 
results with myriocin and S1PP shRNA to support the hypothesis that ceramides mediate 
much of the TG lowering effects in t10c12 CLA treated adipocytes.  
 
Ceramide signaling is downstream of AMPK and can increase AMPK activity 
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AMPK is a key target during t10c12 CLA treatments of adipocytes, as its inhibition by 
compound C abolishes the effects of t10c12 CLA  [6]. As demonstrated above (Figure 
2B), either C2 or SKI-II is sufficient to mediate TG loss in adipocytes in the absence of 
t10c12 CLA, raising the question of whether ceramide-mediated TG loss requires 
activated AMPK.  To answer this, adipocytes were treated with C2 or SKI-II in the 
presence or absence of 10 µM compound C (Figure 5A). For comparison, the ability of 
compound C to interfere with TG loss in the presence of t10c12 CLA is also shown. A 
considerable reduction in TG levels occurs in the presence of C2 or SKI-II, but this 
response is not affected by the presence of compound C (Figure 5A). Therefore, we 
conclude that C2 and SKI-II act downstream or independently of AMPK to mediate TG 
loss in adipocytes.  
 
We also measured the activity of AMPK in the presence of these compounds. The active 
form of AMPK can be detected with an antibody specific for its phosphorylated active 
state [29]. 50 µM t10c12 CLA activates p-AMPK, relative to p-AMPK levels in LA 
treated adipocytes (Figure 5B). Surprisingly, both C2 and SKI-II activated AMPK in 50 
µM LA or t10c12 CLA to equivalent p-AMPK levels (Figure 5B). Thus, although AMPK 
is not required for TG loss in C2 or SKI-II treated adipocytes (Figure 5A), these 
compounds activate AMPK.  
 
C2 and SKI-II activate NF-κB independently of AMPK 
An inflammatory response is an important functional component of TG loss in t10c12 
CLA treated adipocytes, and NF-κB is activated by t10c12 CLA as part of this 
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inflammatory response [3,14]. As an additional comparison between the response of 
adipocytes to t10c12 CLA and their response to C2 or SKI-II, we examined the amount 
of active NF-κB present in the nucleus. The ability of 100 µM t10c12 CLA treatment to 
activate NF-κB is partially dependent on AMPK as compound C attenuates this response 
(Figure 6A). Treatment with either C2 or SKI-II activates NF-κB in adipocytes treated 
with either 50 µM LA or t10c12 CLA (Figure 6B). NF-κB activation occurs equally in 
C2 or SKI-II treated adipocytes whether compound C is present or absent (Figure 6C). 
This indicates that C2 or SKI-II act downstream or independently of AMPK to activate 
NF-κB.  
 
Apoptosis in t10c12 CLA treated adipocytes is a ceramide-dependent response 
Measurement of the amounts of cellular DNA per well in treated adipocytes supports a 
role for t10c12 CLA in causing apoptosis as t10c12 CLA treated adipocytes have less 
total DNA (Figure 7). Addition of C2 ceramide or SKI-II caused similar levels of 
apoptosis as reflected in the lower amounts of total cellular DNA (Figure 7). Inhibition of 
the ceramide pool levels in t10c12 CLA treated adipocytes by concurrent inhibition of 
biosynthesis and entry from S1P by combinations of myriocin or FB1 and knockdown of 
SIPP by shRNA attenuated apoptosis (Figure 7). This result suggests that t10c12 CLA-
mediated apoptosis in adipocytes is mediated in large part by ceramides.   
 
Discussion 
The objective of our metabolic profiling analysis was to gain insight into signaling 
pathways affected by t10c12 CLA. Our analysis of adipocytes after 12 h of exposure to 
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t10c12 CLA, indicated there were significant changes in lipid pathways, as well as in 
sphinganine and sphingosine levels in the ceramide pathway. This study focused on the 
ceramide pathway due to its important roles in many aspects of cell biology and cell 
signaling [15-17]. Our functional assays indicate ceramide/sphingolipids are necessary 
for efficient t10c12 CLA-mediated TG reductions in adipocytes. Surprisingly, increased 
ceramide/sphinonglipid levels are sufficient for lowering TG levels in adipocytes. It is 
unclear how much of these responses are due to the physical properties of 
ceramide/sphingolipids in cell membranes where they can create lipid rafts, alter 
membrane fluidity, and interact with key membrane proteins, or whether ceramide-
stimulated signaling pathways are also participating [30].  
 
An earlier report on the effects of t10c12 CLA on ceramide levels in adipocytes observed 
that the rate of ceramide biosynthesis was attenuated when measured from radiolabeled 
acetate or pyruvate [31]. This is consistent with the reduce rate of de novo fatty acid 
biosynthesis in t10c12 CLA treated adipocytes [7,31].  However, the abundant pools of 
pre-existing fatty acids and ceramides in adipocytes should allow for ceramide synthesis, 
salvage, and interconversion from existing components even when de novo fatty acid 
biosynthesis from two-carbon units is attenuated. Therefore, as total ceramide levels were 
not directly measured in this earlier report, it does not contradict our findings of increased 
ceramide/sphingolipid levels in t10c12 CLA treated adipocytes.  
 
We discuss some of the known responses in adipocytes treated with t10c12 CLA [5] with 
regards to possible roles of ceramide/sphingolipids in these responses. T10c12 CLA 
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affects a number of biological processes including: increased energy expenditure and 
fatty acid oxidation [7,32]; increased NFKB, inflammation, and prostaglandin levels 
[3,14]; activation of AMPK and repression of fatty acid biosynthesis [6,31]; insulin 
resistance via suppression of glucose transporter 4 (GLUT4) expression and function [33]; 
and apoptosis in adipocytes and adipose tissues [11,34].  
 
Energy metabolism and ceramide activation of AMPK  
Activated AMPK is required for TG loss in t10c12 CLA-treated adipocytes [6,14]. 
Activated AMPK increases fatty acid oxidation and energy production while decreasing 
fatty acid biosynthesis [6,31]. Increasing ceramide/sphingolipid levels by addition of C2 
ceramide activated AMPK in adipocytes as described here or in an INS-1 pancreatic beta 
cell line [35]. Sphingosine was elevated 3.6 fold in t10c12 CLA-treated adipocytes, and 
sphingosine can be phosphorylated by sphingosine kinase to produce S1P, which 
activates AMPK in hepatocytes [36]. FTY720, an analog of S1P, can stimulate AMPK 
activity in adipocytes and is associated with an anti-obesity effect in obese mice [37]. 
Ceramides occur in mitochondria and can affect mitochondrial membrane permeability, 
respiratory chain function, oxidative phosphorylation, and apoptosis [17,38], and may 
account for some of the increased fatty acid oxidation occurring in t10c12 CLA-treated 
adipocytes.   
 
Increased NF-κB and inflammation 
Increased NF-κB activity is observed in t10c12 CLA treated adipocytes and this 
increased activity is necessary for the TG loss response in adipocytes [3]. NF-κB activity 
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is associated with an inflammatory response, including prostaglandin biosynthesis, which 
is required for TG loss [12,14]. Our results demonstrate that exogenous chemicals that 
increased ceramide/sphingolipid levels activated NF-κB, and although not measured here, 
presumably stimulate an inflammatory response. Our results suggest that increased 
ceramide levels could be fully or partially responsible for NF-κB activation in t10c12 
CLA treated adipocytes.  
 
Insulin resistance via suppression of glucose transporter 4 (GLUT4) expression and 
function  
Insulin stimulates the translocation of GLUT4 to the plasma membrane from internal 
storage vesicles. T10c12 CLA interferes with this process as plasma membrane localized 
GLUT4 is reduced through a NF-κB-dependent process [3]. Lowering glycosphingolipid 
levels in 3T3-L1 adipocytes results in increased amounts of GLUT4 plasma membrane 
levels [39]. Assuming higher levels of ceramide/sphingolipids result in higher 
glycosphingolipid levels, the enhanced ceramide/sphingolipids levels in t10c12 CLA 
treated adipocytes could account for the reduced transport of GLUT4 to plasma 
membranes [3]. In white and brown adipocytes, ceramides interfere with GLUT4 gene 
expression, possibly through by down regulation of C/EBP-alpha expression, a 
transcription factor essential for the expression of GLUT4. This provides another possible 
ceramide-mediated mechanism in t10c12 CLA-treated adipocytes for reducing GLUT4 
plasma membrane levels [40,41].  
 
Apoptosis in adipocytes and adipose tissues 
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T10c12 CLA mediates reductions in adipocyte and white adipose tissue cell numbers in 
mice in part by apoptosis [11,34]. Ceramides are known to stimulate apoptosis in 
adipocytes [42,43]. Our results demonstrate that concurrent inhibition of ceramide de 
novo biosynthesis and entry from S1P strongly attenuate t10c12 CLA-mediated apoptosis. 
This result suggests the ceramide/sphinoglipid pathway is a major apoptotic signaling 
pathway in t10c12 CLA-mediated apoptosis.  
 
In conclusion, our results strongly suggest that the increased sphingosine, sphinganine, 
and ceramide levels observed in t10c12 CLA treated adipocytes have functionally 
important roles in the TG loss response that occurs. The TG lowering effects of 
ceramides in these in vitro cultures appear to contradict instances in animals where 
inhibition of ceramide de novo biosynthesis attenuated obesity symptoms, facilitating 
weight reduction, better energy metabolism, and improved insulin sensitivity [18].  
Additional studies are required to elucidate the differences in these in vitro and in vivo 
systems.  
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Table 1. Relative sphingolipid levels in 3T3-L1 adipocytes after t10c12 CLA treatment 
Metabolitea CLA vs LA 0.5 h CLA vs LA 12 h 
Sphinganine  1.46   9.81* 
Sphingosine  1.38   3.65* 
aSix replicates of 3T3-L1 adipocytes, treated with 100 µM LA or t10c12 CLA for 0.5 or 
12 h, were analyzed by metabolite profiling on GC/MS, LC/MS, and LC/MS/MS systems 
(Metabolon, Durham, NC). 
*p ≤ 0.05, for a t-test between the LA and CLA treatments at each time.  
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Figure Legends 
 
Figure 1. Biosynthetic pathway of ceramide and sphingolipids.  
Entry into the pathway occurs by biosynthesis via serine palmitoyltransferase or 
dephosphorylation of S1P  by sphingosine-1-phosphate phosphatase (S1PP). The enzyme 
targets of myriocin, fumonisin B1, and sphingosine kinase inhibitor SKI-II are also 
shown as are the targets of shRNA used in this study.  
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Figure 2. Ceramide and TG levels in treated 3T3-L1 adipocytes.  
(A) Ceramide levels were measured in adipocytes 24 h after addition of LA or t10c12 
CLA (CLA) with or without 30µM C2 ceramide (C2) or 10µg/ml of an inhibitor of 
sphingosine kinase (SKI-II) that is expected to increase ceramide levels. Immunoblot 
monoclonal antibody detection of ceramides is shown above the bar graph displaying the 
quantitation of the blot. (B) Triglyceride levels 24 h after 3T3-L1 adipocytes were treated 
50 µM LA or t10c12 CLA (CLA) with or without 30 µM C2 ceramide or 10µg/ml SKI-II. 
(C) Triglyceride levels 24 h after 3T3-L1 adipocytes were treated 50 µM LA or t10c12 
CLA (CLA) with or without 20 µM fumonisin B1 (FB1) or 50 µM myriocin (Myri.). (D) 
Ceramide levels were detected and quantitated as in A. Adipocytes were treated for 24 h 
with 100µM LA or t10c12 CLA, with or without 20 µM FB1 or 50 µM myriocin to 
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t10c12 CLA treated adipocytes. Each bar represents the mean ± SEM (n=3), a 
representative experiment of at least three independent experiments is shown. Means not 
sharing a common letter differ, p≤0.05. 
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Figure 3. shRNA knockdown of SPTLC and S1PP: effects on TG and ceramide levels. 
(A) and (C). Immunoblot analysis of whole cell extracts isolated 24 h after 3T3-L1 
adipocytes were treated with 100 nM of short hairpin RNA (shRNA) against non-target 
(sh-Non), or against Sphingosine-1-Phosphate Phosphatase 1 (sh-S1PP), or against Serine 
Palmitoyltransferase 1 long chain subunit (sh-SPTLC), or transfection reagent only 
(Control). Lanes marked by 1/3 have one third of the indicated samples loaded. (B) 
100µM LA or t10c12 CLA were added 24 h after adding 100 nM of shRNA against non-
target, S1PP, or SPTLC. TG levels were measured 24 hr after fatty acid additions. (D). 
Adipocytes were treated as described in B and ceramide levels were determined by 
immunoblot (shown at the bottom of the panel) and their quantitation is shown by the 
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bars. A representative experiment of at least three independent experiments is shown for 
each panel. Each bar represents the mean ± SEM (n=3). Means not sharing a common 
letter differ, p≤0.05.  
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Figure 4. Inhibition of both biosynthetic entry points into ceramides affects TG and 
ceramide levels.  
 (A) Immunoblot analysis 24 h after 3T3-L1 adipocytes were treated with 100 µM LA or 
t10c12 CLA in the presence of 100 nM shRNA against non-target (sh-Non) or S1PP (sh-
S1PP), and with or without 20 µM Fumonisin B1 (FB1) or 50 µM Myriocin (Myri). (B) 
TG levels after 3T3-L1 adipocytes were treated as in A. A representative experiment of at 
least three independent experiments is shown for each panel. Each bar represents the 
mean ± SEM (n=3). Means not sharing a common letter differ, p≤0.05.  
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Figure 5. Ceramide signaling is downstream of AMPK. 
(A) TG levels in 3T3-L1 adipocytes that were untreated (Control) or treated with 30 µM 
C2-ceramide (C2) or 10 µg/ml SKI-II or 100 µM t10c12 CLA, with (+) or without (-) 10 
µM AMPK inhibitor Compound C (Comp. C). (B) Immunoblot analyses of AMPK and 
activated AMPK (p-AMPK) of cytoplasmic proteins isolated 12 h after addition of 50 
µM LA or t10c12 CLA, with or without 30 µM C2-ceramide or 10 µg/ml SKI-II. A 
representative experiment of at least three independent experiments is shown for each 
panel. Each bar represents the mean ± SEM (n=3). Means not sharing a common letter 
differ, p≤0.05. 
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Figure 6. Ceramides activate NF-κB independently of activated AMPK.   
(A) 3T3-L1 adipocytes were treated with 100 µM LA or t10c12 CLA for 12h, with or 
without 10µM Compound C. Nuclear extracts were analyzed by immunoblot for NF-κB 
and β-actin, and their relative levels of NF-κB and β-actin are displayed. (B) As in A 
except 50 µM LA or t10c12 CLA was used, with or without 30 µM C2-ceramide or 10 
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µg/ml SKI-II. 12h nuclear protein immunoblot analyses for the amount of NF-κB and β-
actin with or without either 30 µM C2-ceramide or 10µg/ml SKI-II. (C) 3T3-L1 
adipocytes in serum were treated with or without 30 µM C2-ceramide or 10µg/ml SKI-II 
in the presence (+) or absence (-) of 10 µM Compound C (Comp. C). Nuclear extracts 
were analyzed by immunoblot for NF-κB and β-actin, and their relative levels of NF-κB 
and β-actin are displayed. A representative experiment of at least three independent 
experiments is shown for each panel. Each bar represents the mean ± SEM (n=3). Means 
not sharing a common letter differ, p≤0.05. 
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Figure 7. Ceramides cause apoptosis in 3T3-L1 adipocytes.  
3T3-L1 adipocytes were assayed for DNA amounts, as a percentage of control levels, as 
an indicator of apoptosis after various treatments.  (A) DNA amounts after 50 or 100 µM 
LA or t10c12 CLA treatments, with or without 30 µM C2-ceramide or 10 µg/ml SKI-II. 
B) DNA amounts after 100 µM LA or t10c12 CLA treatments, with non-target shRNA 
(sh-Non) or shRNA targeting S1PP (Sh-S1PP) and either myriocin (Myri.) or 20 µM 
Fumonisin B1 (FB1). A representative experiment of at least three independent 
experiments is shown for each panel. Each bar represents the mean ± SEM (n=3). Means 
not sharing a common letter differ, p≤0.05. 
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Supplemental Figure 1. Monoclonal antibody to ceramides does not detect C2 ceramide. 
10 and 20 nmoles of C2 ceramide were spotted onto PVDF membrane as well as lipid 
soluble extracts from adipocytes treated with 100 µM LA (LA) or t10c12 CLA (CLA) 
and analyzed by immunoblot analysis with an antibody that detects ceramides. Complete 
recovery of the 60 nmoles of C2 used per well at the standard 30 µM concentration 
would result in 1.2 nmoles of C2 per spot, therefore the 10 and 20 nmole amounts are 
approximately 8x and 17x more than the maximum C2 levels possible. 
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T10c12 CLA has been shown to reduce body fat in number of models, including mice, rat, 
pig, cultured mice and human adipocyte. However, its delipidation effect in human 
studies is still controversial. Despite numerous biological process like inflammation and 
apoptosis have been report associated with t10c12 CLA, its mechanisms remain unclear. 
Besides, high doses of t10c12 CLA may cause side effects, including lipodystrophy, 
insulin resistance, hyperinsulinemia and liver steatosis in mice, which impede its 
application in humans. The goal of this research is to discover some of the mechanisms 
utilized by t10c12 CLA.  
 
Our studies demonstrated cross regulation of sirtuin 1, AMPK and PPARγ was occurring 
in t10c12 CLA treated adipocyte. Inhibitors or activator of Sirtuin 1 decreased or 
increased AMPK activity in t10c12 CLA treated adipocytes. Sirtuin 1 may affect AMPK 
activity via deacetylation of protein kinase LKB1, which activate AMPK by 
phosphorylation.  T10c12 CLA treatment also caused more Sirtuin 1 binding to PPARγ 
and NCoRI, which reduces PPARγ activity, leading to reduced transcription of lipogenic 
genes. On the other hand, inhibition of AMPK reduced Sirtuin 1 activity by affecting the 
NAD+/NADH ratio generated in fatty oxidation. AMPK also decreased PPARγ activity 
by phosphorylation. Agonists or antagonists of PPARγ caused reductions or increases in 
the activity of AMPK and Sirtuin 1, respectively, demonstrating the repressive effect 
PPARγ has on the activities of these proteins. Given that the effect of AMPK and PPARγ 
on lipolysis and lipogenesis, these data suggest an approach that nutritional supplements 
which inhibit PPARγ activity and/or increase AMPK/Sirtuin 1 activity will promote 
t10c12 CLA induced delipidation.   
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Our studies also revealed the role of ceramide/sphingolipid played in t10c12 CLA 
induced delipidation. Elevated ceramide/sphingolipids pathway is functionally required 
for t10c12 CLA-mediated delipidation. Increased ceramide levels strongly promoted 
triglyceride loss. Inhibition of de novo ceramide biosynthesis attenuated t10c12 CLA 
induced delipidation and apoptosis. Increased ceramide levels by C2 ceramide treatment 
increased AMPK and NF-κB activity in t10c12 CLA treated adipocytes. Inhibition of 
AMPK did not impair triglyceride loss or NF-κB activation when ceramide levels were 
elevated by C2 ceramide. These data suggest that ceramide signaling is downstream of 
AMPK and can increases AMPK activity. In addition, measurement of the amounts of 
cellular DNA indicated that increased ceramide levels caused apoptosis, which is consist 
with apoptosis occurring during t10c12 CLA treatment. Inhibition of the ceramide levels 
attenuated triglyceride loss and apoptosis induced by t10c12 CLA. This suggests that 
t10c12 CLA induced apoptosis is mediated in large part by ceramide. Yet, sphingolipid 
metabolites can have opposite effects on cell survival and apoptosis. How these 
sphingolipids contribute to t10c12 CLA induced delipidation needs further study.  
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